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Abbreviations 
 
µg microgram 
ACE  angiotensin converting enzyme  
ACS acyl Co A synthase 
am ante meridian 
ANP atrial natriuretic peptide 
AP-1 activator protein 1 
Apo-A-1 apolipoprotein A-1 
Apo-A-2 apolipoprotein A-2 
Apo-A-5 apolipoprotein A-5 
Apo-C-3 apolipoprotein C-3 
AU arbitrary units 
B2M β-2-microglobulin 
bpm  beats per minute 
cMI chronic myocardial infarction 
COL1A1 collagen 1A1 
CPT-1 carnitine palmitoyl transferase 1 
d day 
DNA deoxyribonucleic acid 
DOCA deoxycorticosterone acetate 
ET-1 endothelin-1 
EtOH Ethanol 
FA fatty acids 
FABP fatty acid binding protein 
FATP fatty acid transport protein 
FA-βox / FAO   fatty acid β oxidation 
FBG     fibrinogen gene 
Feno Fenofibrate 
FFA free fatty acids 
GLUT-1 glucose transporter-1 
HDL high density lipoprotein 
HF heart failure 
HPRT Hypoxanthin-guanin-phosphoribosyltransferase 
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HR heart rate 
ICAM  intercellular adhesion molecule 
IL-6 interleukin-6  
JNK  c-Jun N-terminal kinases 
kg kilogram 
KO knock out 
L32 mitochondrial ribosomal protein L32 
LAD left anterior descending coronary artery 
LDL low density lipoprotein 
LPL lipoprotein lipase 
LV left ventricular 
LV dP/dtmax left ventricular maximum delta pressure / delta time  
LV dP/dtmin left ventricular minimum delta pressure / delta time 
LVEDP left ventricular end-diastolic pressure 
LVPs left ventricular maximum systolic pressure 
MCAD medium chain acyl-coenzyme A dehydrogenase 
mg milligram 
MHC-PPARα mice mice with cardiac-restricted overexpression of 
PPARα 
mM millimolar 
mmol millimol 
mRNA messenger ribonucleic acid 
MyHC myosin heavy chain 
MyHCβ myosin heavy chain β 
NaCl Sodium chloride 
NF-κB  nuclear factor kappa-light-chain-enhancer of 
activated B cells 
ng nanogram 
OPN osteopontin 
p.o. per os 
PBS phosphate buffered saline 
PDK-4 pyruvate dehydrogenase kinase, isozyme-4 
pm post meridian 
PPARs peroxisome proliferator-activated receptors 
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PPARα peroxisome proliferator-activated receptor alpha 
PPRE peroxisome proliferator response elements 
RNA ribonucleic acid 
rpm rotations per minute 
RT-PCR real time polymerase chain reaction 
RV right ventricular  
RXR retinoid X receptor 
s second 
TIMP1 tissue inhibitor of metalloproteinase 1 
TNFα  tumor necrosis factor-alpha 
VCAM-1  vascular cell adhesion molecule 1 
VLDL     very low density lipoprotein 
WHO World Health Organization 
WT wild type 
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1. Introduction 
 
1.1 Heart failure 
 
Heart failure is a progressive clinical syndrome which is characterized by the inability 
of the heart to pump or fill with a sufficient amount of blood through the systemic 
circulation. This condition can result from any structural or functional disorder of the 
heart (Mann et al. 2005). The symptoms of heart failure vary depending on the 
affected ventricle, but are most frequently characterized by shortness of breath upon 
exertion and peripheral or lung oedema. Heart failure is usually chronic, it 
deteriorates progressively, leading to loss of exercise capacity, dyspnoea, and 
ultimately, death. 
 
In epidemiological studies, heart failure accounts for almost 30 % of the mortality in 
the world (WHO, World health report 2006). Despite important progress made in its 
management using ß-blockers, ACE inhibitors, AT1 antagonists and diuretics in the 
last decades, heart failure remains associated with a long-term prognosis of 50% 
mortality within 5 years of diagnosis (Halapas et al. 2008, Frigerio et al. 2005, Cohn 
et al. 2000).  
 
The main cause for the development of heart failure is coronary heart disease, 
accounting for approximately 60 % of cases. In the majority of cases the triggering 
event is an initial myocardial infarction. About 30% of heart failure patients develop 
heart failure due to long-term hypertension (Lloyd-Jones et al. 2002). Other causes 
for heart failure include valvular diseases and genetic or toxic cardiomyopathies 
(ESC 2008). 
 
Besides the functional abnormalities, heart failure is characterized by accompanying 
alterations in cardiac morphology at the organ, tissue and cellular level. These 
alterations include left ventricular and cardiomyocyte hypertrophy, interstitial fibrosis 
and a dysregulation of the composition of interstitial matrix. 
Together, these features comprise a phenomenon which is frequently referred to as 
“cardiac remodelling”. Alone and in combination, myocardial remodelling contributes 
to the functional decline of the heart.  
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In the beginning of the disease, the heart can compensate remodelling processes by 
increasing contractility, frequency and end-diastolic volume (Kempf et al. 2007). 
Those changes are also accompanied by an early activation of the adrenergic 
nervous system and salt- and water-retaining systems (renin-angiotensin-
aldosterone-system) in order to preserve cardiac output (Eichhorn et al. 1996, 
Eisenhofer et al. 1996, Hasking et al. 1986).  In the short term, these systems are 
able to restore cardiovascular function to a normal range, with the result that the 
patient remains asymptomatic. However, with time the sustained activation of these 
systems can lead to secondary end-organ damage within the ventricle, with 
enhanced left ventricular remodelling and subsequent cardiac decompensation 
(Mann et al. 2005). Therefore, counteracting the adrenergic system and the renin-
angiotensin-aldosterone-system are, nowadays, the two most important treatment 
options for heart failure patients. In fact, the introduction of ACE inhibitors and β-
blockers has largely contributed to the amelioration in mortality and morbidity, due to 
improvement of cardiac remodelling and subsequent cardiac function (Cohn et al. 
2000). 
 
Nevertheless, despite the enormous progress in the treatment of heart failure, its 
prognosis remains poor and the need for new therapeutic options to improve cardiac 
remodelling continues to be great. Huge efforts are therefore being undertaken in 
academic as well as industry based research, to understand better the mechanisms 
underlying the pathogenesis of heart failure, and to identify novel targets for the 
prevention of cardiac remodelling. 
 
1.2 Peroxisome proliferator-activated receptors (PPARs)  
 
One receptor, which seems to be involved in those remodelling processes and in the 
modulation of the progression of heart failure, is the peroxisome proliferator-activated 
receptor alpha (PPARα), which belongs to the family of the peroxisome proliferator-
activated receptors (PPARs). 
 
PPARs were first described in 1976 by Lazarow and de Duve. As nuclear hormone 
receptors (Isseman and Green 1990), PPARs regulate a multitude of genes involved, 
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among others, in lipid and glucose homeostasis and in the remodelling processes 
seen in the heart. 
The PPAR family includes three members: PPARα, PPARβ/δ and PPARγ. All PPAR 
receptors subtypes have similar structures and mode of actions but bind to different 
target genes and are activated by different compounds. 
 
The exact structure of the PPARs was described by Zoete et al. (2007), Gearing et 
al. (1994), Motojima (1993) and Dreyer et al. (1992). 
PPAR receptors contain an N-terminal domain that regulates PPAR activity, a DNA-
binding domain that binds to a peroxisome proliferator response element, a domain 
for a cofactor, and a C-terminal ligand-binding domain which determines ligand 
specificity (Ferré 2004, Tugwood et al. 1992). 
PPAR receptors regulate the transcription of target genes by forming heterodimers 
with the retinoid X receptor (RXR) and by binding to specific peroxisome proliferator 
response elements in the promoter region of target genes (Kliewer et al. 2001, Wan 
et al. 2000, Ijpenberg et al. 1997) (Figure 1.1).  
 
   
Figure 1.1: Binding of PPARα agonist on target genes in the liver; RXR: retinoid-X-receptor, 
APOA1: apolipoprotein A1, HDL: high density lipoprotein, FA-βox: fatty acid β oxidation, FBG: 
fibrinogen gene 
 
In the inactivated state, PPARs are bound to corepressor proteins. Upon binding to 
their ligands, PPARs dissociate from their corepressors and recruit coactivators, 
including a PPAR-binding protein and the steroid receptor coactivator-1 (Llopis et al. 
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2000). Thereafter, the PPAR/RXR heterodimer activates the transcription of target 
genes or antagonize their activity. 
 
Agonists of the PPARγ subtype (thiazolidinediones) are currently used for the 
treatment of diabetes mellitus (Raji et al. 2002, Kudzma 2002). However, use of 
those compounds is associated with an increased risk to develop heart failure. This 
phenomenon is related to the potential of the thiazolidinediones to induce weight gain 
and fluid retention (Nesto et al. 2003). 
 
PPARβ/δ agonists are not commercialized at present, but they are supposed to have 
a role in cell differentiation and lipid metabolism. 
 
The present study focuses on the PPARα subtype because this subtype seems to be 
the most promising in the therapy of heart failure, due to its prominent role in 
myocardial remodelling (see below). 
 
1.3 Peroxisome proliferator-activated receptor α (PPARα) 
 
PPARα is ubiquitously expressed. In the heart, PPARα modulates glucose and lipid 
homeostasis and also has remodelling functions (Mukherjee et al. 1997, Braissant et 
al. 1996, Kliewer et al. 1995) (Figure 1.2). But PPARα is also highly expressed in 
tissues with high lipid β-oxidation rates, such as liver, muscle and adipose tissues, 
where this receptor has an important regulating function in lipid and glucose 
metabolism (Mukherjee et al. 1997, Braissant et al. 1996, Kliewer et al. 1995).  
 
Endogenous PPARα agonists are fatty acids, lipid metabolites (Kliewer et al. 2001) 
and eicosanoids such as leukotriene B4, 8-(S)-hydroxyeicosatetraenoic acid and 15-
deoxy-∆12,14–prostaglandin J2 (15d-PGJ2) (Kliewer et al. 1997, Devchand et al. 1996, 
Kliewer et al. 1995, Forman et al. 1994).  
   
Exogenous PPARα agonists are the fibrates, a class of drugs which are used to treat 
hyperlipidaemia (Fruchart et al. 2006, Staels et al. 1998, Issemann and Green 1990). 
On the one hand, effects of the fibrates, such as clofibrate and fenofibrate, on lipid 
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metabolism of patients have been convincingly established in randomized clinical 
trials (e.g.: DAIS, FIELD and ACCORD trials) where they decreased triglycerides and 
LDL cholesterol and increase HDL cholesterol. 
 
 
 
Figure 1.2: Effects of PPARα on the heart; ANP: atrial natriuretic peptide, CPT-1: carnitine 
palmitoyl transferase 1, MyHC: myosin heavy chain, PDK-4: pyruvate dehydrogenase kinase, 
isozyme-4, TIMP1: tissue inhibitor of matrix metalloproteinase 1 
 
PPARα is highly expressed in tissues with elevated capacity for fatty acid β-oxidation 
(FAO) and is an important transcriptional regulator of myocardial energy and lipid 
homeostasis, through modulation of key enzymes of the FAO (Finck et al. 2002, 
Watanabe et al. 2000). Indeed, PPARα directly regulates different genes involved in 
fatty acids uptake and oxidation as well as lipoprotein metabolism through 
peroxisome proliferator response elements (PPRE). Free fatty acids (FFA) uptake is 
increased through fatty acid transport protein (FATP). Once in the cell, fatty acids are 
esterified and activated by acyl Co A synthase (ACS) or bind to fatty acid binding 
protein (FABP). Finally free fatty acids are catabolized through fatty acid-β oxidation 
where the majority of enzymes, such as medium chain acyl-coenzyme A 
dehydrogenase (MCAD) or carnitine palmitoyl transferase 1 (CPT-1), are directly 
regulated by PPARα (van Raalte et al. 2004). PPARα agonists lower triglyceride 
PPARα
Metabolic shift Remodeling
 Increased FA oxidation
CPT-1
 Decreased glucose oxidation
PDK-4
 Hypertrophy
ANP, MyHC
 Fibrosis
Collagen
 Interstitial matrix regulation
TIMP1, Osteopontin
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plasma levels by directly increasing activity of lipoprotein lipase (LPL) or indirectly 
increasing LPL activity by decreasing apolipoprotein C-3 (Apo-C-3, inhibitor of LPL) 
and increasing apolipoprotein A-5 (Apo-A-5, activator of LPL). Furthermore by 
reducing triglyceride stores, PPARα agonists are able to reduce very low density 
lipoprotein (VLDL) levels. Finally, PPARα agonists increase high density lipoprotein 
(HDL) cholesterol, by increasing activity of apolipoprotein A-1 (Apo-A-1) and A-2 
(Apo-A-2) in the liver (Kersten 2008, Staels et al. 1998). But PPARα is also supposed 
to indirectly regulate lipid homeostasis by regulating glucose homeostasis. Indeed, it 
has been described that PPARα is able to bind to glucose and glucose metabolite 
and so may decrease FAO (Hostetler et al. 2008). But this effect could also be due to 
the direct regulation of enzymes involved in the glucose pathway, such as pyruvate 
dehydrogenase kinase, isozyme-4 (PDK-4) and the glucose transporter 1 (GLUT-1) 
(Panagia et al. 2005). 
 
On the other hand, effects on heart failure by fibrate compounds have yet not been 
studied in patients. In fact, heart failure was an exclusion criterion in patients for the 
clinical trials. However, the available non-clinical data collected in animal studies 
indicate promising effects of PPARα in heart failure. 
 
In experiments, PPARα has been described to have a lipid independent anti-
inflammatory effect through direct and indirect inhibition of genes induced by the 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) including 
vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule (ICAM), 
cyclooxygenase 2 (COX-2), interleukin-6 (IL-6) and tumor necrosis factor-alpha 
(TNFα) (Schiffrin 2005) (Figure 1.2). Furthermore PPARα activation can reduce 
fibrosis via reducing the expression of activator protein 1 (AP-1), and inhibition of 
endothelin-1 (ET-1) and the expression of collagen I and III, (Ogata et al. 2002). 
Endothelin-1 is also an important mediator of hypertrophy development. PPARα 
agonists negatively modulate the ET-1 pathway by regulation of AP-1 binding activity 
and inhibition of the c-Jun N-terminal kinases (JNK) pathway and the formation of c-
Fos / c-Jun heterodimers (Li et al. 2008, Irukayama-Tomobe et al. 2004).  
 
Furthermore, the expression of PPARα seems to be reduced in patients with 
hypertensive heart disease (Goikoetxea et al. 2005) or in diabetic patients with non 
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ischaemic heart failure (Razeghi et al. 2002). Accordingly, a decrease of PPARα 
mRNA expression is found in preclinical heart failure models, such as mice and rats 
with aortic banding (Young et al. 2001, Barger et al. 2000, Sack et al. 1997) and rats 
with chronic myocardial infarction (Morgan et al. 2006). 
 
However, conflicting data exist in some forms of heart disease regarding the 
protection by PPARα. Schupp et al. (2005) reported that in patients with dilated 
cardiomyopathy PPARα expression is increased. There are several literary sources 
which suggest that the overexpression of PPARα in heart results in the development 
of cardiomyopathy. It has been reported that hearts of mice with cardiac-restricted 
overexpression of PPARα (MHC-PPARα) exhibit signs of diabetic cardiomyopathy 
including ventricular hypertrophy and systolic dysfunction subsequent to increased 
myocardial fatty acids β-oxidation rates and decreased glucose oxidation rates (Finck 
et al. 2002). Furthermore, it seems that treatment of healthy WT mice with PPARα 
agonists induces cardiomycocyte degeneration and necrosis, due to increased fatty 
acid oxidation and subsequent accumulation of oxidative stress intermediates, an 
effect not observed in PPARα KO mice (Pruimboom-Brees et al. 2006). Sambandam 
et al. (2006) also showed a deterioration of cardiac recovery after ischaemia / 
reperfusion in isolated hearts from MHC-PPARα mice. 
Finally, it has been reported that reactivation of PPARα in early stages of heart 
failure development could be deleterious by accumulating lipids in the myocardium 
and worsening cardiac dysfunction. Young et al. (2001) showed that reactivation of 
PPARα with a PPARα agonist, resulted in severe depression of cardiac power and 
efficiency in the hypertrophied heart because of the prevention of substrate switching 
in an aortic banding study in rats. To maintain its contractile function, the 
hypertrophied heart decreases its reliance on fatty acids as a major substrate for ATP 
generation while increasing its reliance on glucose as a fuel, mainly through 
regulation of PPARα. However, long term down regulation of PPARα and FAO may 
contribute to energy starvation (lower ATP production through Glucose oxidation) of 
the myocardium and cardiac lipotoxicity (storage of lipid in the myocyte followed by 
apoptosis). The process which at first appears to be adaptive may turn out 
maladaptive in the longer term (Balakumar et al. 2007, Ogata et al. 2004). 
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In summary, the literary sources show that PPARα is downregulated in heart failure 
development and that overexpression of PPARα could be detrimental in the recovery 
after an initial event. However, there are no data yet available concerning the 
differentiation between PPARα activity levels and protection in ischaemia or long-
term hypertension induced heart failure in animal models, nor in clinical studies. 
Furthermore, several publications described a number of pathways, in which PPARα 
is involved and beneficial, but its effects on the main features of myocardial 
remodelling, hypertrophy, fibrosis and interstitial matrix regulation, and the 
subsequent cardiac dysfunction have not been clearly established, as yet, in long 
term models of ischaemia and hypertension induced heart failure. 
 
The availability of both specific exogenous PPARα activators and PPARα KO mice 
(see 3.1) represent a suitable tool box to study the biological roles of PPARα in 
health and disease. PPARα agonists allow an activation of PPARα, PPARα KO mice 
permit to study effects correlated to a lack of PPARα protein and a lack of activation 
of the PPARα induced  target genes. 
 
1.4 Aim of the study 
 
The aim of this study was to investigate the role of PPARα in the remodelling 
processes related to heart failure, in models of ischaemia and hypertension induced 
heart failure, the two most important causes of heart failure development in patients.  
To reflect the ischaemia induced heart failure, the model of chronic myocardial 
infarction in mice was used. This model, induced by permanent ligation of the left 
anterior descending coronary artery (LAD), resembles the pathophysiological 
changes of remodelling and deterioration of systolic and diastolic cardiac function in 
patients with ischaemia induced heart failure.  
To mimic hypertension induced heart failure, the deoxycorticosterone acetate 
(DOCA) salt model was used. DOCA mimics hyperaldosteronism and induces 
hypertension with pronounced end-organ damage in heart with hypertrophy, fibrosis 
and cardiac dysfunction, reflecting the pathophysiological changes observed in 
patients with hypertension.  
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If the presence of PPARα is protective in heart failure, the following effects can be 
expected: 1./ Lack of PPARα is detrimental in heart failure development and 2./ 
Activation of PPARα ameliorates heart failure development. 
To investigate these, the effects of abrogation of PPARα activity in KO mice were 
compared to normal activity in WT mice and activation of PPARα by the PPARα 
agonist fenofibrate in the two aforementioned models. 
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2. Materials 
 
2.1 Animals 
 
PPARα wild-type mice (129S1/SvImJ) were purchased from Charles River, Sultzfeld, 
Germany. 
PPARα knock-out mice (129S4/Sv Jae-Ppara-tm1 Gonz) were bred in the breeding 
station of Bayer HealthCare AG, Wuppertal, Germany. 
All mice were 6-8 weeks old, weighed 20-22 g and were male. 
Mice were held in single cages (Type II) on chipped wood, regular pellet chow for 
mice and rats (Provimi Kiba AG, Kaiseraugst, Germany), with free access to 
tapwater. 
Animal rooms had a constant temperature and humidity and a 12 hours day (light) / 
night (dark) rhythm (from 6.30 am to 6.30 pm). 
 
2.2 Drugs 
 
   
           A: Fenofibrate                     B: Ramipril              C: DOCA 
Figure 2.1: Structure of chemicals 
 
 Fenofibrate 
 
Fenofibrate (Figure 2.1, A) is a specific agonist of the PPARα subtype. It is approved 
for the treatment of hyperlipidaemia and is marketed under the brand name of 
“Fenobeta®“ in Germany. 
Fenofibrate was purchased from Sigma-Aldrich, Munich, Germany. 
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 Ramipril 
 
Ramipril (Figure 2.1, B) is an inhibitor of the angiotensin converting enzyme (ACE). It 
is approved for the treatment of hypertension and chronic heart failure and is 
marketed under the brand name of “Delix®“ in Germany. 
Ramipril was purchased from Sigma-Aldrich, Munich, Germany. 
 
 DOCA (deoxycorticosterone acetate) 
 
DOCA (Figure 2.1, C) is an aldosterone agonist and as such binds to the 
mineralocorticoid receptor. This chemical is used in animal experiments to increase 
blood pressure. 
DOCA was purchased from Innovative Research of America, Sarasota, FL, USA. 
 
 Carprofen (Rimadyl®) 
 
Carprofen (Rimadyl®) is a non steroidal anti-inflammatory drug (inhibitor of 
cyclooxygenase-2) and was administered post-operationaly at a dose of 5µg / g body 
weight after appropriate dissolution. 
Carprofen was purchased from Pfizer, Karlsruhe, Germany. 
 
2.3 Chemicals 
 
The following chemicals were used for the biomarker analysis: 
 
Chloroform Merck, Darmstadt, Germany 
DNAse RNAse free Gibco by Invitrogen, Heidelberg, Germany 
ImProm-II Reverse Transcription 
System  
Promega, Mannheim, Germany 
 
Isopropanol Merck, Darmstadt, Germany 
Superscript-II RT-PCR Kit  Invitrogen, Heidleberg, Germany 
TaqMan Universal Master Mix  Eurogentec, Brussels, Belgium 
TRIzol reagent  Invitrogen, Carlsbad, CA, USA 
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All other chemicals were of the highest quality available and purchased from 
commercial suppliers (see Appendix 12.1.1). 
 
2.4 Material 
 
2.4.1 Equipment  
 
 Equipment for the biomarker analysis 
 
ABI Prism 7700 sequence detection 
facility 
Applied Biosystems, Framingham, MA, USA 
 
Centrifuge 5417R Eppendorf, Wesseling-Berzdorf, Germany 
Centrifuge, Minifuge 2 Heraeus Christ GmbH, Osterode, Germany 
FastPrep FP120 cell disrupter  Bio 101 Thermo Savant, Illkirch, France 
Lysing matrix D tubes  MP biomedicals, Solon, OH, USA 
MS1 minishaker  IKA®, Staufen, Germany 
NanoDrop ND-1000 spectrophotometer  NanoDrop Technologies Wilmington, DE, USA 
 
 Equipment for the haemodynamic measurements 
 
Animal Bio Amp ML136 (EKG)  
Micro - Tip ® catheter transducer, SPF 
621, 1.4F, 65cm 
Millar instruments Inc., Houston, TX, USA 
 
Powerlab System 4/25 
 
ADI Instruments by Föhr Medical Instruments 
GmbH, Seeheim-Ober-Beerbach, Germany 
Pressure control unit PCU 2000 Millar instruments Inc., Houston, TX, USA 
 
All other used equipments are part of the standard laboratory equipment and listed in 
the Appendix 12.1.2. 
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2.4.2 Surgical instruments and threads  
 
Surgical instruments were purchased from Aesculap and Martin GmbH, Tuttlingen, 
Germany. Surgical threads were purchased from Ethicon, St.-Stevens-Woluwe, 
Belgium (Appendix 12.1.3). 
 
2.4.3 Computer and software 
 
For data analysis and processing, a conventional personal computer system was 
used with Windows XP using following softwares: Genedata Expressionist software, 
Chart 5 for windows, GraphPad Prism 4.02, Microsoft Office Excel and Microsoft 
Office Word. 
 
2.5 Solutions 
 
The active compounds, Fenofibrate and Ramipril, were dissolved in a vehicle 
solution, composed of 10 % Ethanol, 40 % Solutol and 50 % water. The vehicle and 
all active compounds were prepared as stock solution, without water and frozen away 
as aliquots. Aliquots were weekly supplied with water, to treat the animals.  
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3. Methods 
 
All experiments conformed to the German federal animal protection law and were 
approved by the legal district authority. 
 
3.1 PPARα KO mice 
 
PPARα KO mice were purchased from Jackson Laboratories, Maine, USA and the 
breed was kept by crossing the progenies in the Bayer Healthcare breeding station, 
Germany, laboratory of Dr. Hagelschuer. 
 
Engineering of the PPARα KO mouse was first described by Lee et al. in 1995. 
Briefly, a targeting plasmid containing a neomycin resistance and a herpes simplex 
virus thymidine kinase was constructed and inserted between the PstI and SphI sites 
in exon 8 of the ligand-binding domain of the PPARα gene. This targeting construct 
was introduced in Sv/129 mouse embryonic stem cells via electroporation.  
Embryonic stem cell clones were injected in C57BL/6N blastocysts. Male chimeras 
were mated to C57BL/6N female, and germ line transmission was scored by the 
presence of agouti offspring in the F1 litter. 
PPARα KO mice show complete transcription of mRNA for PPARα, but the resulting 
protein contains a non-sense mutation and is not functional. KO mice do not respond 
to PPARα agonists. Furthermore, these mice do not show phenotypical changes 
compared to WT littermates (Gonzalez 1997), but they do show age dependent lipid 
accumulation and fibrosis in liver and heart (Howroyd et al. 2004). Those changes 
appear commonly after the 6th month of age. To circumvent interactions between 
these changes and the development of heart failure in the cMI and DOCA models, 
mice at the starting age of six to eight weeks were used in these studies. 
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3.2 Chronic myocardial infarction (cMI): Ischaemia induced 
heart failure 
 
The chronic myocardial infarction model was first described in rats by Pfeffer et al. in 
1979. It resembles the pathophysiological changes of remodelling  and deterioration 
of systolic and diastolic cardiac function in patients with ischaemia induced heart 
failure. 
 
In this study, 140 male WT and 104 male KO mice were subjected to pre-
anaesthesia by 5 % Isofluran in a mix of oxygen/pressurized air (2/1) and intubated. 
Thereafter mice were intubated and anaesthesia was continued with 1.2 – 1.5 % 
Isofluran with 140-150 strokes/min and 10 µl strokes volume/g mouse. 
Mice were fixed in a slight dorso-lateral position and left leg stretched out cranial on a 
heating panel (40 °C). Before start of the surgery, the surgery field was shaved and 
disinfected with Cutasept F skin disinfectant, mice were injected with 5 mg/kg/sc 
Carprofen in the popliteal fold and their eyes were covered with Panthenol. 
Incision was placed at the level of the left elbow. With two micro suture tying forceps 
the M. pectoralis profundus was separated from the M. pectoralis superficialis. The 
chest was opened between the 3rd and the 4th rib and spread with an eyelid spreader. 
The pericardium was opened with two micro suture tying forceps and the LAD 
visualized. 
With a Prolene 6/0 thread (0.7 metric, TF-6, EH7814H), the permanent occlusion was 
settled in the proximal 3rd of the LAD with 3 single knots.  
After occlusion, the myocardium distal the knots became pale, due to the interrupted 
blood supply. 
After inflation of the lung, the ribs and pectoralis muscles were adapted separately 
using Vicryl 6/0 (0.7 metric, TF1, V234H). Finally the skin was sutured using Ethibone 
5/0 (1 metric,V-18, 6913H). 
 
After surgery, Isofluran was turned off, the wound was cleaned with NaCl and coated 
with Nebacetin powder spray. 
Mice were kept ventilated until they showed spontaneous respiration. 
After awakening, mice were replaced in cages on heating panels to avoid 
hypothermia. 
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 Treatment groups 
 
After surgery, mice were examined daily to supervise their general condition. 
Fenofibrate was used as a specific PPARα agonist. 
Treatment with Ramipril, an ACE inhibitor, was used as a standard reference. 
Mice were randomly divided into 8 groups: 
Sham WT (n=12) and KO (n=7) 
Placebo WT (n=19) and KO (n=9) 
Fenofibrate WT (n=16) and KO (n=8) 
Ramipril WT (n=16) and KO (n=10) 
All mice received treatment with either Vehicle, Fenofibrate (80 mg/kg/d) or Ramipril 
(10 mg/kg/d).  
Treatment was initiated one week after surgery and lasted for 8 weeks (Figure 3.1). 
 
 
Figure 3.1: chronic myocardial infarction study plan 
 
3.3 DOCA: Hypertension induced heart failure 
 
The DOCA model was first described by Friedman et al. in 1948 in rats. It is used to 
mimic the pathophysiological changes in hypertension induced heart failure. DOCA 
treated rats develop pronounced heart and kidney damage with increased heart 
hypertrophy and fibrosis and kidney dysfunction. 
 
In this study, 70 male WT and 70 male KO mice were subjected to pre-anaesthesia 
by 5 % Isofluran in a mix of oxygen/pressurized air (2/1). Thereafter they were placed 
on the right side on an heating panel (40 °C) and hung by the upper incisive in a 
narcosis mask, where they continuously were ventilated with 1.2 – 1.5 % Isofluran 
and allowed to breath spontaneously. Before start of the surgery, the surgery field 
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was shaved and disinfected with Cutasept F skin disinfectant, mice were injected 5 
mg/kg/sc Carprofen in the neck and their eyes covered with Panthenol. 
 
 Nephrectomy of the left kidney 
 
A 7-10 mm horizontal skin cut was placed behind the last rib and 3 mm beneath the 
lombal musculature. Vertical incision of the musculature was placed above the left 
kidney. Thereafter, the kidney was cautiously pushed out of the abdomen with help of 
a curved anatomical forceps. Fatty tissue was separated from the kidney and the 
blood vessels were freed. A ligature was placed below the left kidney with an 
Ethibone 5/0 thread (1 metric,V-18, 6913H) and kidney was removed. 
Finally the abdominal muscles were sutured with a continuous suture and a Vicryl 6/0 
thread (0.7 metric, TF1, V234H). 
 
 DOCA pellet implantation 
 
DOCA pellets (150 mg DOCA, 60 days release) were placed subcutaneously in the 
popliteal fold of the anaesthetized, nephrectomised mice. 
From the cut, skin was released from the musculature with dissecting forceps toward 
the left knee. After obtaining a vast pocket, a DOCA pellet was placed and skin was 
sutured using Ethibone 5/0 thread (1 metric, V-18, 6913H). 
 
After surgery, Isofluran was turned off, wound was cleaned with NaCl and coated 
with Nebacetin powder spray. 
After awakening mice were replaced in cages, on heating panels to avoid 
hypothermia. 
 
 Treatment groups 
 
After surgery, mice were examined daily to supervise their general condition. 
Mice were randomly divided into 8 groups: 
Sham WT (n=10) and KO (n=10) 
Placebo WT (n=15) and KO (n=15) 
Fenofibrate WT (n=14) and KO (n=15) 
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Ramipril WT (n=13) and KO (n=13) 
All mice received a treatment with either Vehicle, Fenofibrate (80 mg/kg/d) or 
Ramipril (10 mg/kg/d).  
Furthermore, DOCA mice received 1 % NaCl in the drinking water. Only sham 
operated mice received normal drinking water. 
Treatment was initiated one day after surgery and lasted for 42 days (6 weeks) 
(Figure 3.2). 
 
 
Figure 3.2: DOCA study plan 
 
3.4 Medication 
 
For both experiments, mice were treated with the following compounds. 
Vehicle, Fenofibrate or Ramipril in the following concentrations: Fenofibrate: 80 
mg/kg/d and Ramipril: 10 mg/kg/d. 
All substances were given orally dissolved in 10 ml/kg/d of vehicle.  
 
3.4.1 Vehicle (Placebo) 
 
Sham and Placebo groups were given Vehicle medication. 
Vehicle was composed of 10 % Ethanol, 40 % Solutol and 50 % water. 
The mix of Solutol and Ethanol without water was portioned in 50 mL Falcon tubes, 
for a weekly use and frozen by -20 °C. 
Every week a new Falcon tube was thawed and 20 mL water was added. 
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3.4.2 Fenofibrate 
 
Fenofibrate groups were treated with 80 mg/kg/d p.o. Fenofibrate in 10 % Ethanol, 40 
% Solutol and 50 % water.  
3.696 g Fenofibrate was dissolved in 184.8 ml Solutol and 46.2 ml Ethanol before 
start of treatment and then portioned without water in 50 mL Falcon tubes, for a 
weekly use and frozen by -20 °C. 
Every week a new Falcon tube was thawed and 20 mL water was added. 
 
3.4.3 Ramipril 
   
Ramipril groups were treated with 10 mg/kg/d p.o. Ramipril in 10 % Ethanol, 40 % 
Solutol and 50 % water.  
462 mg Ramipril was dissolved in 184.8 ml Solutol and 46.2 ml Ethanol before start 
of treatment and then portioned without water in 50 mL Falcon tubes, for a weekly 
use and frozen by -20 °C. 
Every week a new Falcon tube was thawed and 20 mL water was added. 
 
3.5 Metabolic cages / Diuresis 
 
In the DOCA model, diuresis experiments were performed in PPARα WT and KO 
mice. 
Baseline (0-Diuresis) levels were measured one week before surgery. 
Final-Diuresis levels were measured one week before haemodynamic measurements 
(in the 5th week after surgery). 
 
 Metabolic cages 
 
Mice were placed in metabolic cages for 24 hours. During this time they received 
water and food ad libitum. 
At 0-diuresis, all animals received normal drinking water. 
At final-diuresis, DOCA mice received 1 % NaCl in drinking water, whereas Sham 
mice received normal drinking water. 
Urine and faeces were collected in two separated containers. 
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After 24 hours, each urine sample was separately collected, weighed and finally 
frozen by -20 °C until analysis. 
 
 Analysis of urine samples 
 
Urine samples were analyzed by the department of clinical chemistry, Bayer 
HealthCare AG, Wuppertal, Germany, laboratory of Dr. Ingo Loof. 
Investigated parameters were: Urine volume, protein content, urea content, creatinine 
content, Na+ content and K+ content. 
Urine volume was evaluated by weighing with a balance. 
Other urine parameters were evaluated using commercial kits from Roche 
diagnostics and Eppendorf-Netheler-Hinz GmbH (Appendix 12.2.1). 
 
3.6 Haemodynamic measurements 
 
Mice of the chronic myocardial infarction model were subjected to haemodynamic 
measurements 9 weeks after surgery. 
Mice of the DOCA model were subjected to haemodynamic measurements 6 weeks 
after surgery. 
After the measurements organs and blood samples were collected. 
 
 Computer program 
 
To monitor left ventricular pressure, the Chart 5 program for windows was used. 
A Micro - Tip® catheter transducer, 1.4 F was used as a pressure sensor and 
connected to an amplifying box to allow the computer assisted monitoring of blood 
pressure. 
The pressure tip catheter was calibrated before each measurement. For the 
calibration, the electrical 0, 25 and 100 mV points were tested. 
 
 Haemodynamics 
 
Mice were pre-anaesthetized with 5 % Isofluran in a mix of oxygen/pressurized air 
(2/1) and placed in ventilation masks on heating panels (40°C). Thereafter, mice 
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were exposed to 1.2 – 1.5 % Isofluran, allowed to breath spontaneously and were 
collocated on the back and the throat was shaved and disinfected with Cutasept F 
(skin disinfectant). 
A cut of one cm length was done on the median line of the throat. 
After blunt preparation of the sub cutaneous fatty tissue the two salivary glands were 
visualized and separated in the median line to free the trachea. 
Subsequently the A. carotis dextra was prepared. For this purpose the M. 
sternocleidomastoideus was released, the A. carotis dextra was separated from the 
N. vagus and finally released from the surrounding tissue.  
Three ligation threads were placed underneath the A. carotis dextra. 
The cranial thread was ligated as cranial as possible to impair blood flow. 
The distal thread was fastened with a mosquito clamp and the vessel subjected to 
traction, as far as the blood supply was impaired. 
With a curved 26G needle a hole was punched as proximal as possible, underneath 
the ligature, in the vessel. Thereafter the pressure tip catheter (1.4F) was introduced 
in this hole and pushed until the distal thread. 
With the middle thread, a knot was placed above the pressure tip catheter and the 
distal thread was released, to allow the catheter to be pushed into the left ventricle. 
Once the pressure tip catheter placed in the A. carotis dextra, the blood pressure was 
monitored. 
After one minute, the pressure tip catheter was pushed forward into the left ventricle. 
Mice were allowed to stabilize for two minutes, until the monitoring started. 
Finally, after the systolic and diastolic pressure had been monitored for two minutes, 
the pressure tip catheter was removed from the left ventricle. 
After measurements, blood samples were taken and mice killed by cervical 
dislocation. Finally organ samples were collected. 
 
 Analysis 
 
Measurements were analyzed by the Chart 5 program for Windows. 
Systolic and diastolic ventricular pressures were measured, and from those 
parameters heart rate, LVEDP, dP/dtmax, dP/dtmin and tau were calculated. 
From each mouse a set of data was analyzed and mean and standard deviations 
were calculated. 
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3.7 Blood samples 
 
Venous blood samples from all mice were taken in 1.2 mL lithium heparin tubes. 
Blood was collected after haemodynamic measurements under anaesthesia. 
The abdominal wall was opened from caudal to cranial on both side. The obtained 
skin and muscle lab was then held on the cranial side to discover the abdominal 
cavity. Intestines were pushed on the left side of the mice to get to the right V. iliaca 
interna. The vein was then punctured with a Monovette 20 G needle and the blood 
collected. 
 
After blood collection, lithium heparin tubes were centrifuged by 6000 rpm for 10 
minutes by 4 ° C. Plasma was collected / pipetted and conserved in 1.5 mL 
eppendorf tubes at -20 ° C for further analysis. 
 
 Lipid profile 
 
To determine lipid plasma profiles of mice, plasma samples were analyzed in the 
Cobas integra 400 plus analyzer, using photometry (enzymatic colour test) in specific 
commercial kits, purchased from Roche Diagnostics GmbH (Appendix 12.2.2). 
Lipid profiles were composed out of triglycerides, total cholesterol, LDL cholesterol 
and HDL cholesterol. 
 
3.8 Necropsy 
 
3.8.1 Organs 
 
Mice were killed by cervical dislocation. 
Heart, without atrium and divided into left and right ventricle, lung, liver and right 
kidney were collected, washed in PBS, weighed and shock frozen on carbohydrate 
ice.  
All organs were conserved at -80 °C. 
3.8.2 Morphometric analysis 
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In cMI and DOCA models, morphometric analyses of the organs were performed. For 
this analysis mice and organs were separately weighed. 
Afterward a quotient between organ weight and body weight was calculated. 
 
Organ weight (g) x 1000 = quotient (mg/g) 
Body weight (g) 
 
3.8.3 Scoring of infarct sizes 
 
For the cMI model, infarct sizes were scored. 
All left ventricles from the cMI mice were visually classified in 5 categories according 
to the infarct sizes. 
 
1: no infarct (all sham operated mice) 
2: small infarct 
3: medium infarct 
4: big infarct 
5: huge infarct 
 
3.9 Biomarker analyses 
 
Biomarker analyses were performed with help of the department of target discovery, 
Bayer HealthCare AG, Wuppertal, under supervision of Dr. Peter Ellinghaus and 
collaborators. Analyses were done by real time polymerase chain reaction (RT PCR) 
with mRNA samples extracted from collected tissues. 
 
3.9.1 RNA extraction 
 
RNA was extracted from the frozen (-80 °C) left ventricle of all mice to perform RT 
PCR analysis. 
Left ventricles were crushed in precooled mortars on dry ice.  
After crushing, the samples were given in Lysing matrix D tubes and hold on dry ice 
until further handling. 
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Samples were first denatured with 600 µl TRIzol reagent and shaken for 20 s at 4 
m/s in the FastPrep FP120 cell disrupter. 
Thereafter samples were precipitated with 120 µl chloroform and shaken for 10 s on 
a MS1 minishaker. 
They were centrifuged for 15 min and 4 ° C at 1400 rpm (Eppendorf, Centrifuge 
5417R). 
After centrifugation the clear supernatant was removed from samples and pipetted in 
new tubes, and 210 µl Isopropanol were added before vortexing. 
Mixes were placed for 10 min on ice and afterwards centrifuged for 15 min and 4 ° C 
by 1400 rpm (Eppendorf, Centrifuge 5417R). Finally supernatants were removed. 
The pellets were washed twice with 150 µl 80 % EtOH and allowed to dry for 15 min 
at room temperature. 
Pellets were re suspended in 50 µl Ultrapure distilled water DNAse RNAse free and 
stored at -80 ° C. 
 
3.9.2 cDNA synthesis 
 
RNA samples were quantified by a NanoDrop ND-1000 spectrophotometer before 
further processing. 
 
The ImProm-II Reverse Transcription System was used for the DNA digestion and for 
the reverse transcription of the mRNA. 
 
In brief, 1 µg RNA were dissolved in 1 µl ImProm-II 5x reaction buffer 10x (200 mM 
Tris-HCl (pH8.4)), 1 µl Amplifiaction Grade DNAse I and DEPC-water (q.s.p. 10 µl). 
Mixes were than incubated for 15 min at room temperature and stopped by adding 1 
µl 25 mM EDTA. 
Samples were incubated for further 15 min at 65° C on a thermomixer 5436 and 
finally for 1 min on ice. 
 
For the reverse transcription, 2.2 µl Oligo dT Primer were added and samples were 
incubated 5 min at 70 ° C and 5 min on ice. 
During incubation time Master Mix was composed with Nuclease free water (38.6 %), 
ImProm-II 5x reaction buffer 10x (27.1 %), MgCl2 25 mM (20.4 %), 10 mM dNTPs 
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(6.6 %), Recombinant RNAsin Ribonuclease inhibitor, 20-40 U/µl (3.3 %) and 
ImProm-II Reverse Transcriptase, 50 U/µl (3.8 %). 
From the master mix 39.6 µl were added to the samples, which were then incubated 
for 5 min at 25 ° C and 60 min at 42 ° C. 
Finally 147 µl nuclease free water were added and samples stored by -20 ° C until 
the RT PCR analysis. 
 
3.9.3 Real time polymerase chain reaction (RT PCR) analysis 
 
The method of RT PCR was described in the paper by Uckert et al. (2007). 
2.5 % (approximately 40 ng) of cDNA were submitted to amplification with the 
TaqMan Universal Master Mix using the following protocol: denaturation during 15 
seconds by 94 ° C and annealing / extension during 1 minute by 60 ° C for 40 cycles. 
DNA sequences of PCR primers and labeled probes were designed using Primer 
Express, version 1.5 software (Applied Biosystems). The concentration of primers 
and labeled probes was 300 nmol/L and 150 nmol/L respectively. Fluorescense 
signals were measured using an ABI Prism 7700 sequence detection facility (Applied 
Biosystems). 
All measurements were normalized to the expression of transcripts encoding for the 
housekeeping gene hypoxanthin-guanin-phosphoribosyltransferase (HPRT) (Table 
3.1). 
 
Table 3.1:  RT-PCR analysis: sequences of forward and reverse primers and probes used to amplify 
mRNA transcripts. In the studies, HPRT served as a housekeeping gene.  
 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) Probe (5’-FAM-3’TAMRA) 
HPRT GTTGCAAGCTTGCTGGTGAA GATTCAAATCCCTGAAGTACTCA CCTCTCGAAGTGTTGGATACAGGCCA 
L32 ACTGGAGGAAACCCAGAGGC CATCAGGATCTGGCCCTTGA TCGACAACAGGGTGCGGAGAAGG 
B2M GAAGCCGAACATACTGAACTGCTA CCCGTTCTTCAGCATTTGGAT CACAGTTCCACCCGCCTCACATTG 
ANP AGGAGAAGATGCCGGTAGAAGA GCTTCCTCAGTCTGCTCACTCA AGGTCATGCCCCCGCAGGC 
MYHCβ CAGCCATGCCAACCGTATG TCCACGATGGCGATGTTCT ATGCTGTCCGTGCCAATGACGACC 
TIMP1 GTCCCAGAACCGCAGTGAAG CTGATGTGCAAATTTCCGTT TTTCTCCATCACGGGCCGCCTAA 
COL1A1 CAACCTGGACGCCATCAAG GAGGCACAGACGGCTGAGTAG TGCAACATGGAGACAGGTCAGACCTGTG 
PPARα TTGCCACTGTTCAGGGACCT TGTGCAAATCCCTGCTCTCC CGAGGCCTGCGGCCCCAT 
PDK-4 TGCTTTTCTGCGGCAAGAG TAAGCGGTCAGGCAGGATGT CGTCCGCCTGGCCAATATCCTGA 
OPN GCGGTGAGTCTAAGGAGTCCC TGATCAGAGGGCATGCTCAG CGATGTCATCCCTGTTGCCCAGCT 
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3.10 Statistics 
 
The statistical analysis was performed using the GraphPad Prism program. 
For every analyzed parameter and for each group mean and standard deviation 
(SEM) were calculated. Differences between groups were analyzed using a one-way 
ANOVA, followed by the student Newmann-Keuls post hoc analysis or using an 
unpaired t-test.  
All results are represented as mean±SEM. For all graphs statistical significances 
were represented as asteriks: * p<0.05; ** p<0.01; *** p<0.001. 
In the chronic myocardial infarction study one outlier was taken off the study after use 
of the outlier test of Nalimov. 
Admission criteria for the DOCA study were a systolic blood pressure higher than 100 
mmHg at the end of the study. No outliers were taken off the DOCA study. 
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4. Results 
 
4.1 cMI model 
 
4.1.1 Mortality and morphology in WT and KO mice 
 
 Mortality 
 
128 WT mice and 93 KO mice were subjected to permanent ligation of the LAD and 
12 WT and 11 KO mice were subjected to Sham operation. In the first week after 
surgery, mortality of the ligated KO mice was almost twice as high as in ligated WT 
mice, with 40.9 % (n= 38) compared to 22.6 % (n= 29), respectively (Figure 4.1.1). All 
Sham WT (n= 12) and KO (n= 11) mice survived. 
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Figure 4.1.1: Survival curves of Sham and cMI PPARα WT and KO mice one week after surgery,      
** p<0.01, Logrank test 
 
In the following weeks, no further WT mice died in contrary to the KO mice.  
At the end of the study, 72.7 % of Sham (n= 8), 64.3 % of Placebo (n= 9), 53.3 % of 
Fenofibrate (n= 8) and 76.9 % of Ramipril (n= 10) KO mice survived.  
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 Infarct sizes 
 
Infarct sizes were measured semi quantitatively using arbitrary scores.  
As expected, WT and KO Sham mice had an infarct score of 0 (no sign of infarcts) 
after nine weeks (Figure 4.1.2 and Appendix table 1). The WT groups had similar 
infarct sizes with 3.2, 3.4 and 3.0 in the Placebo, Fenofibrate and Ramipril groups, 
respectively. As well, the KO groups had comparable infarct sizes with 3.6, 3.1 and 4 
in the Placebo, Fenofibrate and Ramipril groups, respectively. The infarct scores 
were also comparable between the WT and KO groups, where all mice had medium 
to big size infarcts. 
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Figure 4.1.2: Infarct sizes of Sham and cMI PPARα WT and KO mice after eight weeks of treatment; 
n= 16 (WT), 8 (KO); mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis; $ p<0.05 vs respective WT group; unpaired t-test 
 
 Body weight 
 
At the end of the study, body weights were comparable within WT and KO groups 
(Appendix table 2). However, KO mice, with 25 g in average, were significantly 
smaller than WT mice, with 30g in average (Sham p<0.01 and Placebo p<0.001), 
although they were the same age and the same weight before surgery.  
 
 Heart weight 
 
As an important parameter of cardiac hypertrophy, relative heart weights were 
comparable between WT and KO Sham mice, with 4.2 and 4.3 mg/g, respectively 
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(Figure 4.1.3 and Appendix table 3). A significant increase of 14 % and 12 % of the 
relative heart weight was seen in WT and KO mice, respectively, after nine weeks of 
permanent LAD ligation (p<0.001 and p<0.01 respectively in unpaired t-test).  
Treatment with Ramipril significantly reduced relative heart weight increase to Sham 
levels (p<0.001) in WT animals. Treatment with Fenofibrate had no significant effect 
compared to Placebo mice. 
In KO animals, no amelioration of the relative heart weight was observed after eight 
weeks of treatment with Fenofibrate or Ramipril. 
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Figure 4.1.3: Relative heart weights of Sham and cMI PPARα WT and KO mice after eight weeks of 
treatment; n= 16 (WT), 8 (KO); mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, followed by 
Student-Newmann-Keuls post hoc analysis; $$ p<0.01 vs respective WT group; unpaired t-test;  
Note the absence of an effect of ramipril in the KO mice. 
 
 Ventricular weight 
 
Increase of the heart weight is due to an increase of one or both ventricle weight. 
Therefore weights of the left ventricle + septum and of the right ventricle were 
separately investigated. 
 
o Left ventricular weight 
 
Relative left ventricular weight of Sham KO mice was significantly lower compared to 
Sham WT mice (p<0.05 in unpaired t-test) (Figure 4.1.4 and Appendix table 4). 
An increase of 0.6 and 0.5 mg/g in the relative left ventricular weight was seen in 
Placebo WT and KO mice, respectively, compared to their Sham groups (p<0.001 in 
WT mice). 
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Figure 4.1.4: Relative left ventricular weights of Sham and cMI PPARα WT and KO mice after eight 
weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, 
followed by Student-Newmann-Keuls post hoc analysis; $ p<0.05 , $$ p<0.01 vs respective WT group; 
unpaired t-test;  
Note the absence of an effect of ramipril in the KO mice. 
 
Similar to the relative heart weight, treatment with Ramipril significantly reduced the 
relative left ventricular weight increase to Sham levels (p<0.001) in WT animals. 
Treatment with Fenofibrate had no significant effect on this weight. 
In KO mice, treatment with Fenofibrate or Rampril had no significant effect on the left 
ventricular hypertrophy after eight weeks. 
  
o Right ventricular weight 
 
In WT as well as in KO mice relative right ventricular weights were comparable with 
an average of 0.81 – 0.86 mg/g in all groups (Appendix table 5). 
 
 Organ weights: lung, liver, right kidney 
 
Heart failure may induce congestion in the body circulation. To evaluate this 
possibility, organ weights were measured. Furthermore, PPARα agonists are known 
to induce a peroxisome proliferation, which induces an increase of the liver weight 
(Kliewer et al. 2001). 
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o Lung weight 
 
Relative lung weights were comparable between all WT groups with values of 4.9 – 
5.0 mg/g, but slightly inferior to the KO groups with values of 5.3 -5.5 mg/g (Appendix 
table 6). 
 
o Liver weight 
 
In WT mice, relative liver weights of Sham and Placebo groups were comparable with 
42.2 and 42.3 mg/g, respectively (Figure 4.1.5 and Appendix table 7).  
Treatment with Ramipril induced a significant increase of 8 % of the relative liver 
weight compared to Placebo mice (p<0.01). Furthermore, treatment with Fenofibrate 
induced, as expected, an increase of almost 68 % of the relative liver weight 
compared to Placebo mice (p<0.001).  
On the contrary, liver weights were similar in all KO groups with values of 45.2 – 49.2 
mg/g.  
No congestion of the liver was observed after chronic myocardial infarction. 
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Figure 4.1.5: Relative liver weights of Sham and cMI PPARα WT and KO mice after eight weeks of 
treatment; n= 16 (WT), 8 (KO); mean ± SEM; ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, 
followed by Student-Newmann-Keuls post hoc analysis; $ p<0.05, $$$ p<0.001 vs respective WT group; 
unpaired t-test;  
Note that fenofibrate had no effect on the liver weight in KO mice. 
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o Right kidney weight 
 
All WT groups had similar relative right kidney weights of 7.0 – 7.1 mg/g, apart from 
the Fenofibrate group (Appendix table 8). Eight weeks of treatment with Fenofibrate 
induced a significant increase of 0.6 mg/g of the relative right kidney weight 
compared to Placebo mice (p<0.001). 
In the KO groups, all mice had similar relative right kidney weights of 6.7 – 7.0 mg/g. 
 
4.1.2 Haemodynamics in WT and KO mice  
 
The morphological changes induced by a heart failure are often reflected in 
impairments of the haemodynamic functions of the myocardium. 
 
 Heart rate 
 
Heart rate was similar between all groups in the WT mice with values between 437 
and 454 bpm (Figure 4.1.6 and Appendix table 9). Whereas in the KO mice heart rate 
was higher in the Sham groups than in all other treatment groups with 382 bpm 
compared to values between 337 and 343 bpm. Furthermore, Sham and Placebo KO 
mice had decreased heart rates compared to their respective WT groups (p<0.01 and 
p<0.001, respectively). 
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Figure 4.1.6: Heart rate of Sham and cMI PPARα WT and KO mice after eight weeks of treatment;  
n= 16 (WT), 8 (KO); mean ± SEM; $$ p<0.01, $$$ p<0.001 vs respective WT group; unpaired t-test;  
Note the lower heart rate in KO mice compared to WT mice.  
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 Left ventricular systolic pressure (LVP) 
 
Permanent ligation of the LAD induced a slight decrease of the left ventricular systolic 
pressure in Placebo WT compared to Sham WT and a significant decrease of 
pressure in Placebo KO compared to Sham KO mice (p<0.001) (Figure 4.1.7 and 
Appendix table 10). Furthermore, LVP of Placebo KO mice was significantly reduced 
compared to Placebo WT mice (p<0.001 in unpaired t-test), although it was similar in 
Sham groups. 
In both WT and KO mice, left ventricular systolic pressures were comparable after 
treatment with Placebo and Fenofibrate but significantly reduced by 20 mmHg in WT 
mice and by 16 mmHg in KO mice after treatment with Ramipril (both p<0.001).  
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Figure 4.1.7: Left ventricular systolic pressure of Sham and cMI PPARα WT and KO mice after 
eight weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; ** p<0.01, *** p<0.001 vs respective 
Placebo; ANOVA, followed by Student-Newmann-Keuls post hoc analysis; $$$ p<0.001 vs respective 
WT group; unpaired t-test; 
Note the lower systolic pressure in KO mice with heart failure compared to WT mice. 
 
 Left ventricular end-diastolic pressure (LVEDP) 
 
LVEDP is an important parameter for the diastolic function and relaxation of the heart 
and increases by heart failure. 
In both WT and KO mice, permanent ligation of the LAD resulted in a significant 
increase of LVEDP by 3.3 and 4.8 mmHg, respectively in Placebo compared to their 
respective Sham groups (p<0.01 in WT and p<0.05 in KO in unpaired t-test) (Figure 
4.1.8 and Appendix table 11). 
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Sham KO mice had a significant lower left ventricular end-diastolic pressure than 
Sham WT mice with 6.0 mmHg compared to 10.2 mmHg, respectively (p<0.01). 
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Figure 4.1.8: Left ventricular end diastolic pressure of Sham and cMI PPARα WT and KO mice 
after eight weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05, ** p<0.01 vs respective 
Placebo; ANOVA, followed by Student-Newmann-Keuls post hoc analysis; $$ p<0.01 vs respective WT 
group; unpaired t-test; 
Note the lower LVEDP in Sham KO mice compared to Sham WT mice. 
 
In WT animals, eight weeks of treatment with Fenofibrate tendend to decrease left 
ventricular end-diastolic pressure by 1.5 mmHg compared to Placebo mice, whereas 
treatment with Ramipril significantly decreased LVEDP to levels similar to Sham 
(10.2 mmHg, p<0.01). 
Whereas in KO mice, treatments with Fenofibrate or Ramipril had no effect on the left 
ventricular end-diastolic pressure compared to Placebo mice. 
 
 Contractility (left ventricular dP/dtmax) 
 
The left ventricular dP/dtmax is a parameter for the systolic function and contractility of 
the heart. It is usually decreased in heart failure. 
The dP/dtmax was comparable in Sham WT and KO with values of 7685 and 7613 
mmHg/s, respectively (Figure 4.1.9 and Appendix table 12).  In both WT and KO 
mice, permanent ligation of the LAD induced a significant decrease of the contractility 
in Placebo compared to Sham mice (both p<0.001). However, this decrease was 
significantly more pronounced in the Placebo KO mice compared to the Placebo WT 
mice with values of 4630 mmHg/s compared to 6574 mmHg/s, respectively (p<0.001 
in unpaired t-test). 
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Treatment of WT animals with the PPARα agonist Fenofibrate significantly improved 
(p<0.05) contractility after eight weeks compared to Placebo. Treatment with Ramipril 
had no effect. 
On the contrary, treatment with Fenofibrate in the KO mice had no effect on left 
ventricular dP/dtmax, nor had the treatment with Ramipril. 
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Figure 4.1.9: Left ventricular contractility (dP/dtmax) of Sham and cMI PPARα WT and KO mice 
after eight weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05, ** p<0.01, *** p<0.001 vs 
respective Placebo; ANOVA, followed by Student-Newmann-Keuls post hoc analysis; $$$ p<0.001 vs 
respective WT group; unpaired t-test; 
Note the further decreased contractility in operated KO mice compared to their respective WT mice. 
 
 Relaxation (left ventricular dP/dtmin) 
 
As a parameter for relaxation, left ventricular dP/dtmin increases in heart failure. 
Left ventricular dP/dtmin values were slightly higher in Sham KO compared to Sham 
WT mice with -7714 mmHg/s compared to -8986 mmHg/s, respectively (Figure 
4.1.10 and Appendix table 13). 
In both WT and KO mice permanent ligation of the LAD resulted in a significant 
increase (both p<0.001) of the relaxation in the Placebo groups compared to their 
respective Sham groups, but this increase was significantly higher in Placebo KO 
compared to Placebo WT mice, with increases of 45 % and 28 % respectively 
(p<0.001 in unpaired t-test). 
In WT mice, both treatment with Fenofibrate and Ramipril showed a significant 
improvement of the relaxation (both p<0.05). 
On the contrary, PPARα KO mice showed worsened values of left ventricular dP/dtmin 
and none of the treatments could improve the relaxation after eight weeks. 
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Figure 4.1.10: Left ventricular relaxation (dP/dtmin) of Sham and cMI PPARα WT and KO mice after 
eight weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; ** p<0.01, *** p<0.001 vs respective 
Placebo; ANOVA, followed by Student-Newmann-Keuls post hoc analysis; $$$ p<0.001 vs respective 
WT group; unpaired t-test; 
Note the further increased dP/dtmin in operated KO mice compared to operated WT mice. 
 
 Left ventricular relaxation constant tau 
 
A further parameter for the diastolic function and the relaxation of the heart is the left 
ventricular relaxation constant tau. It is usually increased in heart failure. 
Tau was comparable in Sham WT and KO mice with values of 12.4 and 14 ms, 
respectively (Figure 4.1.11 and Appendix table 14). In both WT and KO mice, ligation 
induced a significant increase of tau in Placebo mice compared to their Sham mice 
(both p<0.001). However, this increase was much higher in Placebo KO compared to 
Placebo WT mice with an increase of 19.3 ms compared to an increase of 7 ms, 
respectively (p<0.001 in unpaired t-test). 
In WT mice, treatment with Fenofibrate and Ramipril significantly reduced tau by 15 
% and 30 %, respectively (p<0.05 and p<0.001, respectively). 
However in the KO mice, none of the treatments affected tau.  
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Figure 4.1.11: Left ventricular relaxation constant tau of Sham and cMI PPARα WT and KO mice 
after eight weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; ** p<0.01, *** p<0.001 vs respective 
Placebo; ANOVA, followed by Student-Newmann-Keuls post hoc analysis; $$$ p<0.001 vs respective 
WT group; unpaired t-test; 
Note the increased tau in operated KO mice compared to their respective WT mice. 
 
4.1.3 Biomarker analysis / RT-PCR analysis 
 
 Expression of PPARα and PPARα regulated genes 
 
o PPARα 
 
PPARα expression was similar in Sham WT and KO groups with expression of 1724 
and 1808 arbitrary units (AU), respectively, but significantly increased in Placebo KO 
compared to Placebo WT mice (p<0.01) (Figure 4.1.12 and Appendix table 15). 
PPARα gene expression can be detected in PPARα KO mice due to the design of 
the KO expression plasmid (see methods 3.1) (full mRNA transcript containing a non 
sense mutation resulting in a non functional protein). 
Furthermore, in WT and KO mice, ligation of the LAD resulted in a decrease of the 
PPARα mRNA expression by 54 % and 26 %, respectively, in Placebo compared to 
Sham mice (p<0.01 in WT and p<0.05 in KO). 
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Figure 4.1.12: mRNA expression of PPARα of Sham and cMI PPARα WT and KO mice after eight 
weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, 
followed by Student-Newmann-Keuls post hoc analysis; $$ p<0.01, $$$ p<0.001 vs respective WT 
group; unpaired t-test; 
 
In WT mice, treatment with Fenofibrate or Ramipril could not preserve decrease of 
PPARα mRNA expression. 
In KO mice, Fenofibrate and Ramipril groups showed less reduction of PPARα 
mRNA expression compared to WT mice.  
 
o PPARα regulated genes: Pyruvate dehydrogenase kinase, isozyme-4 (PDK-4) 
 
PDK-4 is a mitochondrial enzyme playing a role in the glucose metabolism and is 
partly regulated by PPARα. 
PDK-4 mRNA expression was tendencially decreased in Sham KO compared to 
Sham WT mice and significantly decreased in Placebo KO compared to Placebo WT 
mice (p<0.05) with values of 3426 AU compared to 5041 AU and 1785 AU compared 
to 4083 AU, respectively (Figure 4.1.13 and Appendix table 16). 
In both WT and KO mice, ligation of the LAD resulted in a tendencial decrease of the 
PDK-4 mRNA expression in Placebo mice compared to their respective Sham 
littermates. 
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Figure 4.1.13: mRNA expression of PDK-4 of Sham and cMI PPARα WT and KO mice after eight 
weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05 vs respective Placebo; ANOVA, 
followed by Student-Newmann-Keuls post hoc analysis; $ p<0.05 vs respective WT group; unpaired t-
test; 
Note the further decreased PDK-4 mRNA expression in KO mice compared to WT mice. 
 
In WT mice and KO mice, mRNA expression of PDK-4 was similar between all 
groups. However, expression levels were lower in KO mice compared to WT mice.  
 
 Markers of hypertrophy 
 
As markers of hypertrophy, the expression of atrial natriuretic peptide (ANP) and 
myosin heavy chain-β (MyHCβ) were analyzed. 
 
o Atrial natriuretic peptide (ANP) 
 
Permanent ligation of the LAD resulted in a significant 2.8 fold and 3 fold increase of 
the ANP mRNA expression in Placebo groups compared to their respective Sham in 
WT and KO mice (both p<0.01) (Figure 4.1.14 and Appendix table 17). 
However, there was a tendency towards reduced ANP mRNA expression in KO 
groups compared to their respective WT groups. 
In WT mice, treatment with Fenofibrate and Ramipril decreased the ANP mRNA 
expression compared to Placebo by 30 % and 47 %, respectively (p<0.01 in 
Ramipril). 
In KO mice, treatment with Fenofibrate or Ramipril did not ameliorate ANP mRNA 
expression compared to Placebo mice.  
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Figure 4.1.14: mRNA expression of ANP of Sham and cMI PPARα WT and KO mice after eight 
weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; ** p<0.01 vs respective Placebo; ANOVA, 
followed by Student-Newmann-Keuls post hoc analysis 
 
o Myosin heavy chain-β (MyHCβ) 
 
In WT and KO Placebo mice, permanent ligation of the LAD induced a 2.7 fold and 
3.8 fold increase of MyHCβ mRNA expression, respectively, compared to their Sham 
mice (p<0.05 in WT and p<0.001 in KO) (Figure 4.1.15 and Appendix table 18). 
However, MyHCβ mRNA expression in KO mice was significantly higher as in WT 
mice (p<0.001 in Sham and Placebo). Indeed the MyHCβ mRNA expression was 
almost seven times as high in Sham KO as in Sham WT mice and almost ten times 
as high in Placebo KO compared to Placebo WT mice. 
Furthermore, in WT mice, treatment with Fenofibrate or Ramipril significantly 
decreased the MyHCβ mRNA expression by 50 % and 70 %, respectively, compared 
to Placebo (p<0.01 in Fenofibrate and p<0.001 in Ramipril). 
In KO mice, on the contrary, treatment with Fenofibrate or Ramipril did not ameliorate 
MyHCβ mRNA expression compared to Placebo. 
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Figure 4.1.15: mRNA expression of MyHCβ of Sham and cMI PPARα WT and KO mice after eight 
weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; ** p<0.01, *** p<0.001 vs respective Placebo; 
ANOVA, followed by Student-Newmann-Keuls post hoc analysis; $$$ p<0.001 vs respective WT group; 
unpaired t-test; 
Note the higher expression of MyHCβ in KO mice compared to WT mice. 
 
 Markers of fibrosis and interstitial matrix remodelling 
 
As a marker of fibrosis, collagen 1A1 (COL1A1) was analyzed and as markers of 
interstitial matrix remodelling, tissue inhibitor of metalloproteinase 1 (TIMP1) and 
osteopontin were analyzed. 
 
o Collagen 1A1 (COL1A1) 
 
Permanent ligation of the LAD tended to increase the collagen mRNA expression in 
Placebo WT compared to Sham WT and a significant increase in Placebo KO 
compared to Sham KO mice (p<0.001) (Figure 4.1.16 and Appendix table 19). 
Furthermore, collagen mRNA expression in KO mice was significantly higher than in 
WT mice (p<0.05 in Sham and p<0.001 in Placebo). Indeed collagen mRNA 
expression was almost four times as high in Placebo KO as in Placebo WT mice and 
almost twice as high in Sham KO as in Sham WT mice. 
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Figure 4.1.16: mRNA expression of collagen 1A1 of Sham and cMI PPARα WT and KO mice after 
eight weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05, vs respective Placebo; 
ANOVA, followed by Student-Newmann-Keuls post hoc analysis; $ p<0.05, $$$ p<0.001 vs respective 
WT group; unpaired t-test; 
Note the higher expression of collagen 1A1 in KO mice compared to WT mice. 
 
In WT mice, treatment with Fenofibrate and Ramipril tended to decrease collagen 
mRNA expression by 20 % and 24 %, respectively, compared to Placebo mice. 
On the contrary, treatment with Fenofibrate or Ramipril in KO mice could not 
influence collagen mRNA expression compared to Placebo mice. 
 
o Tissue inhibitor of metalloproteinase 1 (TIMP1) 
 
In WT and KO Placebo mice, permanent ligation of the LAD induced a 3 and 4.9 fold 
increase of TIMP1 mRNA expression compared to their respective Sham mice 
(p<0.01 in WT and p<0.05 in KO) (Figure 4.1.17 and Appendix table 20). 
Furthermore, TIMP1 mRNA expression was almost four and six times higher in Sham 
and Placebo KO mice as in their respective WT groups (both p<0.001 in unpaired t-
test). 
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Figure 4.1.17: mRNA expression of TIMP1 of Sham and cMI PPARα WT and KO mice after eight 
weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05, ** p<0.01 vs respective Placebo; 
ANOVA, followed by Student-Newmann-Keuls post hoc analysis; $$$ p<0.001 vs respective WT group; 
unpaired t-test; 
Note the higher expression of TIMP1 in KO mice compared to WT mice. 
 
Furthermore, treatment with Fenofibrate and Ramipril in WT mice decreased TIMP1 
mRNA expression by 29 % and 39 %, respectively, compared to Placebo mice. 
In KO mice, treatment with Fenofibrate had no effect any more on TIMP1 mRNA 
expression and treatment with Ramipril significantly increased by almost 70 % TIMP1 
mRNA expression compared to Placebo mice (p<0.01).  
 
o Osteopontin (OPN) 
 
Permanent ligation of the LAD resulted in a three fold and 18 fold increase of the 
osteopontin mRNA expression in Placebo groups compared to their respective Sham 
in WT and KO mice, respectively (p<0.01 in WT and p<0.001 in KO) (Figure 4.1.18 
and Appendix table 21). 
However, OPN mRNA expression in KO groups was on average 5 – 10 fold lower as 
in WT groups. 
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Figure 4.1.18: mRNA expression of osteopontin of Sham and cMI PPARα WT and KO mice after 
eight weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05 vs respective Placebo; 
ANOVA, followed by Student-Newmann-Keuls post hoc analysis; $$ p<0.01 vs respective WT group; 
unpaired t-test; 
Note the lower expression of osteopontin in KO mice compared to WT mice. 
 
In WT mice, treatment with Fenofibrate and Ramipril decreased osteopontin mRNA 
expression by 33 % and 57 %, respectively, compared to Placebo mice. 
On the contrary, in KO mice, treatment with Fenofibrate did not influence osteopontin 
mRNA expression compared to Placebo mice. However, KO mice receiving Ramipril 
treatment had almost twice as high osteopontin levels compared to Placebo mice. 
 
4.1.4 Blood analysis 
 
PPARα is an important regulator of lipid metabolism. Therefore, lipid profiles of the 
mice were determined in their plasma. 
 
 Triglycerides 
 
Triglycerides levels were similar in WT groups, with a tendency towards decreased 
triglycerides in the Fenofibrate group compared to Placebo mice with values of 99 
mg/dL and 108 mg/dL, respectively (Appendix table 22). 
Triglycerides levels were equivalent in KO groups. 
 
 
 
 
 54
 Total cholesterol 
 
In WT mice, total cholesterol levels were similar in Sham, Placebo and Ramipril 
groups with values of 105, 113 and 122 mg/dL, respectively (Figure 4.1.19 and 
Appendix table 23). However, treatment with Fenofibrate significantly increased those 
levels by 40 %, compared to Placebo mice (p<0.001). 
In KO mice, total cholesterol levels were comparable in Sham, Placebo and Ramipril 
mice with values of 128, 120 and 132 mg/dL, respectively, but were significantly 
increased by 13 % after treatment with Fenofibrate (p<0.05). 
Furthermore, cholesterol levels of KO mice were higher as WT mice, with statistical 
significance in the Sham groups (p<0.001 in unpaired t-test). 
 
WT mice
Sham Placebo Feno Ramipril
0
25
50
75
100
125
150
175
***
Ch
o
le
st
er
o
l, 
m
g/
dL
KO mice
Sham Placebo Feno Ramipril
0
25
50
75
100
125
150
175
*
Ch
o
le
st
er
o
l, 
m
g/
dL $$$
$$
 
 
Figure 4.1.19: Total cholesterol plasma levels of Sham and cMI PPARα WT and KO mice after 
eight weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05, *** p<0.001 vs respective 
Placebo; ANOVA, followed by Student-Newmann-Keuls post hoc analysis; $$ p<0.01 vs respective WT 
group; unpaired t-test; 
Note the higher cholesterol plasma levels in KO mice compared to WT mice and the lack of effect of 
fenofibrate in KO mice. 
 
 HDL cholesterol 
 
No differences were seen between Sham and Placebo groups of WT and KO mice 
(Figure 4.1.20 and Appendix table 24). However, plasma levels of HDL cholesterol 
were 33 % and 17 % higher in Sham and Placebo KO mice compared to their 
respective WT mice (p<0.001 in Sham and p<0.01 in Placebo). 
Furthermore, in WT mice, high density lipoprotein levels were similar in Sham, 
Placebo and Ramipril groups with values of 95, 102 and 108 mg/dL, respectively. 
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However, treatment with Fenofibrate significantly increased HDL cholesterol levels by 
48 % compared to Placebo mice (both p<0.001). 
In KO mice, HDL cholesterol levels were comparable in all groups with values 
between 119 and 136 mg/dL. 
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Figure 4.1.20: HDL cholesterol plasma levels of Sham and cMI PPARα WT and KO mice after eight 
weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, 
followed by Student-Newmann-Keuls post hoc analysis; ; $$ p<0.01 vs respective WT group; unpaired 
t-test; 
Note the higher HDL cholesterol plasma levels in KO mice compared to WT mice and the lack of effect 
of fenofibrate in these mice. 
 
 LDL cholesterol 
 
In WT mice, low density lipoprotein levels were similar in Sham, Placebo and 
Ramipril groups with values of 3, 5 and 5 mg/dL, respectively (Figure 4.1.21 and 
Appendix table 25). However, treatment with Fenofibrate induced a significant almost 
3 fold increase of those levels compared to Placebo mice (p<0.001). 
In KO mice, LDL levels were comparable in Sham, Placebo, Fenofibrate and Ramipril 
mice with values of 7, 6, 7 and 8 mg/dL, respectively. 
Furthermore, LDL levels of KO mice were higher as WT mice, with statistical 
significance in the Sham groups (p<0.001 in unpaired t-test). 
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Figure 4.1.21: LDL cholesterol plasma levels of Sham and cMI PPARα WT and KO mice after eight 
weeks of treatment; n= 16 (WT), 8 (KO); mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, 
followed by Student-Newmann-Keuls post hoc analysis; $$ p<0.01, $$$ p<0.001vs respective WT group; 
unpaired t-test; 
Note the higher LDL cholesterol plasma levels in KO mice compared to WT mice and the lack of effect 
of fenofibrate on this level in KO mice compared to WT mice. 
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4.2 DOCA model 
 
For the DOCA model, the same morphological, haemodynamic and biomarker 
analysis as for the cMI model were performed. 
 
4.2.1 Morphology in WT and KO mice 
 
 Body weight 
 
Placebo and Ramipril WT groups were significantly smaller than Sham and 
Fenofibrate WT groups after six weeks of treatment, with weights of 26.8, 27.0, 30.2 
and 28.8g, respectively (Appendix table 26). 
In KO groups, all mice had comparable body weights of 25g in average.  
However, groups of Sham and Placebo KO mice were significantly smaller than 
respective WT groups (Sham p<0.01, Placebo p<0.05), although they were the same 
size and age at the time of the surgery. 
 
 Heart weight 
 
Relative heart weights were similar between Sham WT and KO mice, with 4.4 and 
4.3 mg/g and between Placebo WT and KO mice, with 5.1 and 5.6 mg/g (Figure 4.2.1 
and Appendix table 27). 
DOCA treatment induced a significant increase of the relative heart weight in Placebo 
groups compared to their respective Sham groups of WT and KO mice by 16 and 30 
%, respectively (both p<0.001). 
In WT mice, treatment with Fenofibrate and Ramipril significantly reduced the relative 
heart weight compared to Placebo (both p<0.05). 
In KO mice, no differences between Placebo and Fenofibrate treated mice were seen. 
However, treatment with Ramipril significantly reduced relative heart weight compared 
to the Placebo group (p<0.01). 
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Figure 4.2.1: Relative heart weights of WT and KO mice after six weeks of treatment; n= 15; mean ± 
SEM; * p<0.05, ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by Student-Newmann-
Keuls post hoc analysis; $ p<0.05 vs respective WT group; unpaired t-test; 
Note the lack of effect of fenofibrate in KO mice compared to WT mice. 
 
 Ventricular weights 
 
o Left ventricular weight 
 
Relative left ventricular weights were comparable between Sham WT and KO mice, 
with values of approximately 3.5 mg/g (Figure 4.2.2 and Appendix table 28). 
In WT and KO mice, a significant increase of the relative left ventricular weight by 23 
and 34 %, respectively, was seen in Placebo groups compared to their respective 
Sham groups (p<0.001). 
In WT mice, treatment with Fenofibrate and Ramipril significantly reduced the relative 
left ventricular weight by 7 % compared to Placebo (both p<0.01). 
In KO mice, no differences between Placebo and Fenofibrate treated mice were seen. 
However, treatment with Ramipril significantly reduced relative left ventricular weight 
by 17 % compared to Placebo mice (p<0.01). 
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Figure 4.2.2: Relative left ventricular weights of WT and KO mice after six weeks of treatment; n= 
15; mean ± SEM; * p<0.05, ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by 
Student-Newmann-Keuls post hoc analysis; $ p<0.05 vs respective WT group; unpaired t-test; 
Note the lack of effect of fenofibrate in KO mice compared to WT mice. 
 
o Right ventricular weight 
 
Relative right ventricular weights were comparable in WT as well as in KO groups 
with values between 0.76 and 0.92 mg/g (Appendix table 29). 
 
 Organ weights: lung, liver, right kidney 
 
o Lung 
 
Relative lung weights of Sham groups were similar in WT and KO mice with values of 
5.1 and 5.3 mg/g, respectively (Appendix table 30).  
In Placebo WT and KO mice, DOCA treatment induced a significant increase of the 
relative lung weight compared to their respective Sham groups (both p<0.05 in 
unpaired t-test). 
In WT as well as in KO treatment groups, relative lung weights were comparable to 
their respective Placebo groups. However, KO mice showed higher lung weights as 
WT mice, with statistical significance in Placebo groups (p<0.05). 
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o Liver 
 
Relative liver weights were comparable in Sham WT and KO mice, but significantly 
increased by 31 and 53 %, respectively, in Placebo WT and KO mice compared to 
their respective Sham groups (p<0.001) (Figure 4.2.3 and Appendix table 31). 
Furthermore, Placebo KO mice showed a significant increased relative liver weight 
compared to Placebo WT mice (p<0.01). 
In WT mice, relative liver weights of Placebo and Ramipril treated mice were 
comparable. However, treatment with Fenofibrate induced an increase by 71 % of the 
relative liver weight compared to Placebo mice (p<0.001).  
In KO mice, relative liver weights were comparable in Placebo, Fenofibrate and 
Ramipril treated groups. 
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Figure 4.2.3: Relative liver weights of WT and KO mice after six weeks of treatment; n= 15; mean ± 
SEM; *** p<0.001 vs respective Placebo; ANOVA, followed by Student-Newmann-Keuls post hoc 
analysis; $$ p<0.01, $$$ p<0.001 vs respective WT group; unpaired t-test; 
Note the lack of effect of fenofibrate on the liver weight in KO mice compared to WT mice. 
 
o Right kidney 
 
Relative right kidney weights were comparable in Sham WT and KO mice with values 
of 6.9 and 7.2 mg/g, but significantly increased by 81 % in Placebo WT mice and by 
107 % in Placebo KO mice compared to their respective Sham groups after six 
weeks (both p<0.001) (Figure 4.2.4 and Appendix table 32). 
Furthermore, Placebo KO mice showed a significantly increased relative right kidney 
weight compared to Placebo WT mice (p<0.001). 
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Figure 4.2.4: Right kidney weights of WT and KO mice after six weeks of treatment; n= 15; mean ± 
SEM; * p<0.05, *** p<0.001 vs respective Placebo; ANOVA, followed by Student-Newmann-Keuls post 
hoc analysis; $$$ p<0.001 vs respective WT group; unpaired t-test; 
Note the higher increase of the right kidney weight in placebo KO mice compared to placebo WT mice. 
 
In WT mice, relative right kidney weights were significantly increased after treatment 
with Fenofibrate and Ramipril compared to Placebo mice (both p<0.05). 
In KO mice, relative right kidney weights were similar in Placebo and Ramipril treated 
mice, but significantly decreased in Fenofibrate treated mice compared to Placebo 
mice (p<0.05). 
 
4.2.2 Haemodynamics in WT and KO mice 
 
 Heart rate 
 
In WT and KO mice, Sham and Placebo groups had comparable heart rates of 442, 
425, 474 and 504 bpm (Figure 4.2.5 and Appendix table 33). However, heart rates 
were significantly increased in KO mice compared to the respective WT mice (p<0.05 
in Sham and p<0.001 in Placebo). 
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Figure 4.2.5: Heart rate of WT and KO mice after six weeks of treatment; n= 15; mean ± SEM;  
$
 p<0.05, $$ p<0.01, $$$ p<0.001 vs respective WT group; unpaired t-test; 
Note the higher heart rate in KO mice compared to WT mice. 
 
In WT mice, heart rates were comparable between Sham, Placebo, Fenofibrate and 
Ramipril treated groups. As well, in KO mice heart rates were similar in all groups. 
 
 Left ventricular systolic pressure 
 
In WT and KO mice, Sham groups had comparable left ventricular systolic pressures 
of 120 and 115 mmHg (Figure 4.2.6 and Appendix table 34).  
Furthermore, DOCA treatment resulted in a significant increase of the left ventricular 
systolic pressure by 23 mmHg in Placebo WT mice and by 18 mmHg in Placebo KO 
mice compared to their respective Sham groups (both p<0.001). 
In WT mice, left ventricular systolic pressures were comparable in Placebo and 
Fenofibrate treated groups, but significantly reduced by 10 mmHg after treatment 
with Ramipril compared to Placebo groups (p<0.01). 
In KO mice, left ventricular systolic pressures were similar in Placebo, Fenofibrate 
and Ramipril treated groups. 
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Figure 4.2.6: Left ventricular systolic pressure of WT and KO mice after six weeks of treatment;  
n= 15; mean ± SEM; ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis 
 
 Left ventricular end-diastolic pressure 
 
No significant differences of left ventricular end-diastolic pressure were observed 
between Sham and Placebo WT mice, although there was a tendency towards a 
decrease of LVEDP in Placebo mice by 31 % (Figure 4.2.7 and Appendix table 35). 
In KO mice, no significant differences were seen between Sham and Placebo groups, 
although there was a tendency towards increased LVEDP in Placebo mice by 26 %. 
However, left ventricular end-diastolic pressure was significantly lower in Sham KO 
mice compared to Sham WT mice (p<0.01). 
 
WT mice
Sham Placebo Feno Ramipril
0
5
10
15
LV
ED
P,
 
m
m
 
Hg
KO mice
Sham Placebo Feno Ramipril
0
5
10
15
LV
ED
P,
 
m
m
 
H
g
$$
 
 
Figure 4.2.7: Left ventricular end diastolic pressure of WT and KO mice after six weeks of 
treatment; n= 15; mean ± SEM; $$ p<0.01 vs respective WT group; unpaired t-test; 
Note the lower LVEDP in Sham KO mice compared to Sham WT mice. 
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No significant differences of LVEDP were observed between WT and KO Fenofibrate 
and Ramipril treated groups. 
 
 Contractility (left ventricular dP/dtmax) 
 
Left ventricular dP/dtmax, as a measure of contractility was similar in Sham WT and 
KO mice with values of 7784 and 8054 mmHg/s (Figure 4.2.8 and Appendix table 
36). 
DOCA treatment of mice resulted in a significant increase of left ventricular dP/dtmax 
by 15 % in Placebo WT mice and by 11 % in Placebo KO mice compared to the 
respective Sham groups after six weeks (p<0.05 in WT and p<0.01 in KO in unpaired 
t-test).  
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Figure 4.2.8: Left ventricular contractility (dP/dtmax) of WT and KO mice after six weeks of 
treatment; n= 15; mean ± SEM 
 
In WT and KO mice, left ventricular dP/dtmax of Fenofibrate and Ramipril treated 
groups were comparable to their respective Placebo groups. 
 
 Relaxation (left ventricular dP/dtmin) 
 
Left ventricular dP/dtmin as a measure for relaxation was comparable in all WT and 
KO groups with values between -10319 and -9031 mmHg/s (Appendix table 37). 
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 Left ventricular relaxation constant tau 
 
Left ventricular relaxation constant tau was similar in Sham and in Placebo groups of 
WT and KO mice, with 12.7, 11.5, 14.8 and 15.6 ms, respectively (Figure 4.2.9 and 
Appendix table 38).  
A tendency towards increase of tau by 17 % in Placebo WT mice and by 36 % in 
Placebo KO mice compared to their respective Sham groups was seen after six 
weeks of DOCA treatment. 
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Figure 4.2.9: Left ventricular relaxation constant tau of WT and KO mice after six weeks of 
treatment; n= 15; mean ± SEM; $ p<0.05, $$ p<0.01 vs respective WT group; unpaired t-test; 
Note the lacking effect of fenofibrate and Ramipril on KO mice compared to WT mice. 
 
In both WT and KO mice Fenofibrate and Ramipril treated groups were comparable 
to their respective Placebo groups. 
 
4.2.3 Diuresis in WT and KO mice 
 
 Baseline diuresis (0-Diuresis) 
 
Baseline parameters, such as urine volume, urea and Na+ / K+ quotient, from 
diuresis analysis were comparable in WT and KO groups (Appendix table 39). 
However, Protein / Creatinine quotient was significantly increased by 60 % in KO 
mice compared to their respective WT mice (Figure 4.2.10). 
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Figure 4.2.10: Proteine / Creatinine ratio of WT and KO mice before surgery; n= 15; mean ± SEM; 
ANOVA, followed by Student-Newmann-Keuls post hoc analysis; $ p<0.05, $$ p<0.01 vs respective WT 
group; unpaired t-test; 
Note the higher proteine / creatinine ration in KO mice compared to WT mice. 
 
 Final diuresis 
 
Urine volume tended to be increased in Placebo WT compared to Sham WT mice by 
184 % and significantly increased in Placebo KO compared to Sham KO mice by 433 
% (p<0.05) after six weeks of DOCA treatment (Appendix table 40). Urine volume 
was tendencially further increased in Placebo KO compared to Placebo WT mice (73 
%, p>0.05) and significantly increased in Ramipril treated KO compared to Ramipril 
treated WT mice (88 %, p<0.05). 
Urine urea content was significantly decreased by 62 % and by 74 % in Placebo WT 
and KO mice, respectively, compared to their respective Sham groups (p<0.001) and 
significantly further decreased in DOCA treated KO compared to DOCA treated WT 
mice (p<0.001 for Fenofibrate and p<0.05 for Ramipril treated groups). 
Urine Na+ / K+ quotient was significantly increased by 360 % and by 475 % in 
Placebo WT and KO mice compared to their respective Sham groups (p<0.01) and 
significantly further increased in KO compared to WT mice (p<0.05 in Sham, 
Placebo, Fenofibrate and Ramipril treated mice).  
Urine protein / creatinine quotients were significantly increased by 106 % in Placebo 
WT mice and by 340 % in Placebo KO mice compared to their respective Sham 
groups (both p<0.001) (Figure 4.2.11). 
In WT mice, treatment with Fenofibrate resulted in slightly decreased protein / 
creatinine quotient and treatment with Ramipril in a significant decrease of the 
quotient (p<0.05) compared to the Placebo group. 
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In KO mice treatment with Fenofibrate and Ramipril did not significantly influence the 
protein / creatinine quotient compared to the Placebo group. 
However the quotient was significantly increased by 42 % in Placebo KO compared 
to Placebo WT mice (p<0.05). 
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Figure 4.2.11: Proteine / Creatinine ratio of WT and KO mice after five weeks of treatment; n= 15; 
mean ± SEM; * p<0.05, *** p<0.001 vs respective Placebo; ANOVA, followed by Student-Newmann-
Keuls post hoc analysis 
 
 Difference between baseline and final diuresis 
 
Urine volume between baseline and final measurements was significantly 24 fold 
increased in Placebo WT and 27 fold in Placebo KO mice compared to their 
respective Sham mice (both p<0.05) (Appendix table 41). Furthermore, this 
difference tended to be further increased in Placebo KO compared to Placebo WT 
mice and significantly increased in Ramipril KO compared to Ramipril WT mice (twice 
as high increase in KO compared to WT Ramipril treated mice, p<0.05). In KO mice, 
treatment with Ramipril significantly increased this difference compared to Placebo 
mice (p<0.05). 
Urine urea content between baseline and final measurements was in the tendency 
decreased by 252 % in Placebo KO compared to Sham KO mice and significantly 
decreased by 453 % in Placebo WT compared to Sham WT mice (p<0.001).  
Urine Na+ / K+ quotient between baseline and final measurements was significantly 
increased in Placebo treated WT and KO mice compared to their respective Sham 
mice (p<0.05 in WT and p<0.01 in KO) and significantly further increased in Placebo 
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KO compared to Placebo WT mice (doubling of quotient in KO compared to WT 
mice, p<0.05).  
Urine protein / creatinine quotient between baseline and final measurements was 3.3 
fold increased in Placebo WT mice and 155 fold in Placebo KO mice compared to 
their respective Sham (both p<0.01) (Figure 4.2.12). 
In WT mice, treatment with Ramipril significantly decreased this difference by 40 % 
compared to the Placebo group (p<0.05). 
In KO mice, treatment with Fenofibrate and Ramipril did not significantly influence 
this difference compared to the Placebo group. 
However the difference was significantly decreased by 98 % in Sham KO compared 
to Sham WT mice (p<0.05). 
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Figure 4.2.12: Delta of Proteine / Creatinine ratio of WT and KO mice; n= 15; mean ± SEM; * 
p<0.05, ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by Student-Newmann-Keuls 
post hoc analysis; $ p<0.05 vs respective WT group; unpaired t-test; 
 
4.2.4 Biomarker analysis / RT-PCR analysis 
 
 Expression of PPARα and PPARα regulated genes 
 
o PPARα 
 
PPARα mRNA expression was not significantly downregulated after nephrectomy 
and DOCA treatment (Appendix table 42). 
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o PPARα regulated genes: Pyruvate dehydrogenase kinase, isozyme-4 
(PDK-4) 
 
PDK-4 mRNA expression was decreased in Placebo mice compared to their 
respective Sham mice (p<0.05 in KO mice) (Figure 4.2.13 and Appendix table 43). 
However, expression of PDK-4 was lower in PPARα KO mice compared to their 
respective WT mice (p<0.05 in Placebo mice). 
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Figure 4.2.13: PDK-4 mRNA expression of WT and KO mice after six weeks of treatment;  
n= 15; mean ± SEM; $ p<0.05 vs respective WT group; unpaired t-test; 
 
Treatment with Fenofibrate or Ramipril had no effect on the expression of PDK-4 in 
both WT and KO mice. 
 
 Markers of hypertrophy 
 
As markers of hypertrophy, expression of atrial natriuretic peptide (ANP) and myosin 
heavy chain-β (MyHCβ) were analyzed. 
 
o Atrial natriuretic peptide (ANP) 
 
DOCA treatment of mice resulted in a significant increase of ANP mRNA expression 
levels in Placebo WT and KO mice compared to their respective Sham groups 
(p<0.01 in WT and p<0.05 in KO) (Figure 4.2.14 and Appendix table 44). Although 
ANP mRNA expression was comparable in Sham WT and KO groups, increase was 
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more displayed in DOCA treated KO as in WT mice (3 fold in Placebo WT and 4.3 
fold in Placebo KO mice). 
In WT mice, treatment with Fenofibrate and Ramipril tendencially decreased ANP 
mRNA expression levels by 26 and 30 % compared to Placebo mice, respectively. 
In KO mice, ANP mRNA expression levels were similar in Placebo and Fenofibrate 
treated groups, but tendencially decreased by 41 % after treatment with Ramipril 
compared to Placebo mice.  
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Figure 4.2.14: ANP mRNA expression of WT and KO mice after six weeks of treatment; n= 15; 
mean ± SEM; * p<0.05, ** p<0.01 vs respective Placebo; ANOVA, followed by Student-Newmann-
Keuls post hoc analysis; $ p<0.05 vs respective WT group; unpaired t-test; 
Note the lack of effect of fenofibrate on the ANP mRNA expression in KO mice. 
 
o Myosin heavy chain-β (MyHCβ) 
 
Levels of MyHCβ mRNA expression were almost three times as high in Sham KO as 
in Sham WT mice (p<0.05) and almost 1.6 times as high in Placebo KO as in 
Placebo WT mice (Figure 4.2.15 and Appendix table 45). 
DOCA treatment of mice resulted in a significant 3.3 fold increase of MyHCβ mRNA 
expression levels in Placebo compared to Sham WT mice (p<0.05) and in a 
tendencial increase by 1.8 fold in Placebo KO compared to Sham KO mice. 
In WT mice, treatment with Fenofibrate tendencially decreased MyHCβ mRNA 
expression levels by 30 % compared to Placebo mice. 
In KO mice, no significant differences of MyHCβ mRNA expression levels were 
observed after treatment with Fenofibrate or Ramipril compared to Placebo mice.  
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Figure 4.2.15: MyHCβ mRNA expression of WT and KO mice after six weeks of treatment; n= 15; 
mean ± SEM; * p<0.05 vs respective Placebo; ANOVA, followed by Student-Newmann-Keuls post hoc 
analysis; $ p<0.05 vs respective WT group; unpaired t-test; 
Note the higher expression of MyHCβ in KO mice compared to WT mice. 
 
 Markers of fibrosis and interstitial matrix remodelling 
 
As a marker of fibrosis, collagen 1A1 (COL1A1) was analyzed and as markers of 
interstitial matrix remodelling, tissue inhibitor of metalloproteinase 1 (TIMP1) and 
osteopontin were analyzed. 
 
o Collagen 1A1 (COL1A1) 
 
No significant differences of collagen mRNA expression were seen between groups 
of WT and KO mice (Appendix table 46). 
 
o Tissue inhibitor of metalloproteinase 1 (TIMP1) 
 
DOCA treatment of mice resulted in a 2.8 fold increase of TIMP1 mRNA expression 
levels in Placebo WT compared to Sham WT mice and in a 4.4 fold increase in 
Placebo KO compared to Sham KO mice (Figure 4.2.16 and Appendix table 47). 
Although TIMP1 mRNA expression was comparable in Sham WT and KO groups, 
increase was more displayed in Placebo and Fenofibrate treated KO as in their 
respective WT groups. 
In WT mice, treatment with Fenofibrate and Ramipril tendend to decrease TIMP1 
mRNA expression levels by 18 and 33 %, respectively, compared to Placebo mice. 
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In KO mice, TIMP1 mRNA expression levels were similar in Placebo and Fenofibrate 
treated groups, but tendencially decreased by 64 % after treatment with Ramipril 
compared to Placebo mice.  
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Figure 4.2.16: TIMP1 mRNA expression of WT and KO mice after six weeks of treatment; n= 15; 
mean ± SEM; * p<0.05 vs respective Placebo; ANOVA, followed by Student-Newmann-Keuls post hoc 
analysis 
 
o Osteopontin 
 
DOCA treatment of mice resulted in a 3 and 9 fold increase of osteopontin mRNA 
expression levels in Placebo compared to Sham groups in WT and KO mice, 
respectively (Figure 4.2.17 and Appendix table 48). Although OPN mRNA expression 
was comparable in Sham WT and KO groups, increase was more displayed in 
Placebo and Fenofibrate treated KO as in their respective WT groups. 
In WT mice, treatment with Fenofibrate and Ramipril tendend to decrease OPN 
mRNA expression levels by 39 and 49 %, respectively, compared to Placebo mice. 
In KO mice, OPN mRNA expression levels were similar in Placebo and Fenofibrate 
treated groups, but tendend to decrease by 74 % after treatment with Ramipril 
compared to Placebo mice.  
 
 73
WT mice
Sham Placebo Feno Ramipril
0
500
1000
1500
O
PN
 
ex
pr
es
si
o
n
, 
ar
bi
tr
ar
y 
u
n
its
KO mice
Sham Placebo Feno Ramipril
0
500
1000
1500
O
PN
 
ex
pr
es
si
o
n
, 
ar
bi
tr
ar
y 
u
n
its
$
 
 
Figure 4.2.17: Osteopontin mRNA expression of WT and KO mice after six weeks of treatment;  
n= 15; mean ± SEM; $ p<0.05 vs respective WT group; unpaired t-test; 
 
4.2.5 Blood analysis 
 
 Triglycerides 
 
Triglycerides levels were comparable in Sham and Placebo groups (Figure 4.2.18 
and Appendix table 49).  
DOCA treatment of mice resulted in an increase by 40 and 49 % of triglyceride levels 
in Placebo WT and KO groups compared to their respective Sham groups. 
In WT mice, Placebo and Ramipril treated groups had comparable triglyceride levels, 
but treatment with Fenofibrate tendencially decreased triglyceride levels by 22 % 
compared to Placebo mice. 
In KO mice, Placebo, Fenofibrate and Ramipril treated groups had comparable 
triglyceride levels. 
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Figure 4.2.18: Plasma triglycerides levels of WT and KO mice after six weeks of treatment; n= 15; 
mean ± SEM; * p<0.05 vs respective Placebo; ANOVA, followed by Student-Newmann-Keuls post hoc 
analysis; $ p<0.05, $$ p<0.01 vs respective WT group; unpaired t-test; 
Note the higher triglycerides plasma levels in KO mice compared to WT mice. 
 
 Total cholesterol 
 
Total cholesterol levels were 23 % higher in Sham KO compared to Sham WT mice 
(p<0.001 in unpaired t-test) (Figure 4.2.19 and Appendix table 50). Similarly, Placebo 
KO mice had tendencially higher levels of cholesterol compared to Placebo WT mice 
(+ 47 %). 
Furthermore, a significant increase of the total cholesterol levels by 75 % in Placebo 
WT mice and by 109 % in Placebo KO mice compared to their respective Sham 
groups was seen after six weeks of DOCA treatment (p<0.01).  
In WT mice, total cholesterol levels were comparable in Placebo, Fenofibrate and 
Ramipril treated groups.  
In KO mice, no significant differences in cholesterol levels were seen in all treated 
groups, but cholesterol levels were about 42 % higher compared to WT mice.  
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Figure 4.2.19: Plasma total cholesterol levels of WT and KO mice after six weeks of treatment;  
n= 15; mean ± SEM; ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis; $ p<0.05, $$ p<0.01, $$$ p<0.001 vs respective WT group; unpaired 
t-test; 
Note the higher cholesterol plasma levels in KO mice compared to WT mice. 
 
 HDL cholesterol 
 
High density lipoprotein cholesterol levels were significantly higher in Sham KO 
compared to Sham WT mice (16 %, p<0.01) and significantly increased by 28 % in 
Placebo KO mice compared to Placebo WT mice (Figure 4.2.20 and Appendix table 
51).  
DOCA treatment of mice resulted in a significant increase of HDL cholesterol levels 
by 78 % in Placebo WT mice and by 96 % in Placebo KO mice compared to their 
respective Sham groups (p<0.001 in WT and p<0.01 in KO).  
In WT and KO mice, no significant differences of HDL levels were seen in DOCA 
treated groups after six weeks, but HDL levels were about 41 % higher in KO 
compared to WT groups. 
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Figure 4.2.20: Plasma HDL cholesterol levels of WT and KO mice after six weeks of treatment;  
n= 15; mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, followed by Student-Newmann-
Keuls post hoc analysis; $ p<0.05, $$ p<0.01 vs respective WT group; unpaired t-test; 
Note the higher HDL plasma levels in KO mice compared to WT mice. 
 
 LDL cholesterol 
 
Low density lipoprotein cholesterol levels were significantly higher in KO mice 
compared to WT mice (133 %, p<0.001 in Sham and 78 %, p<0.05 in Placebo) 
(Figure 4.2.21 and Appendix table 52). 
In WT and KO mice, a significant increase of LDL cholesterol levels by 800 % in 
Placebo WT mice and by 586 % in Placebo KO mice compared to their respective 
Sham groups (p<0.001) was observed after six weeks of DOCA treatment.  
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Figure 4.2.21: Plasma LDL cholesterol levels of WT and KO mice after six weeks of treatment;  
n= 15; mean ± SEM; ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis; $ p<0.05, $$ p<0.01, $$$ p<0.001 vs respective WT group; unpaired 
t-test; 
Note the higher LDL plasma levels in KO mice compared to WT mice. 
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In WT and KO mice, no significant differences of LDL levels were seen in DOCA 
treated groups after six weeks, but LDL levels in KO groups were about 86 % higher 
compared to WT groups. 
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5. Discussion 
 
 
The present study demonstrates that PPARα plays a critical role in the development 
of myocardial remodelling related to heart failure. Comparing PPARα knock-out (KO) 
and wild type (WT) mice, the experiments show that the lack of PPARα accelerates 
heart failure development and, using fenofibrate, that activation of PPARα 
ameliorates heart failure through modifying morphology, haemodynamics and 
biomarkers. Altogether, these data suggest that a PPARα agonist may be a new 
therapeutic option for the treatment or prevention of heart failure.  
 
In the majority of cases, heart failure is triggered by an initial ischaemic event, the 
myocardial infarction or, in 30 % of cases, by long time hypertension. To characterize 
the PPARα effects in ischaemia induced heart failure, the chronic myocardial 
infarction (cMI) mouse model was used. To mimic the pathophysiological changes in 
hypertension induced heart failure the DOCA salt mouse model was used.  
The cMI rat model resembles the pathophysiological changes of remodelling and 
cardiac dysfunction seen in patients with ischaemia induced heart failure (Pfeffer et 
al. 1979, Halapas et al. 2008). The cMI rats develop myocardial hypertrophy, 
inflammation and fibrosis resulting in left ventricular systolic and diastolic dysfunction 
with reduced contractility and increased left ventricular enddiastolic pressure. Similar 
effects are seen in the mouse cMI model (Lutgens et al. 1999). 
In the DOCA model hypertension is induced by nephrectomy of one kidney, 
administration of the aldosterone agonist DOCA and feeding of animals with a high 
salt diet (Friedman et al. 1948, Halapas et al. 2008). DOCA treated rats and mice 
develop pronounced heart and kidney damage with increased heart hypertrophy and 
fibrosis, and kidney dysfunction (Kim et al. 1997). The development of morphological 
changes in the heart is much more pronounced than the haemodynamic ones which 
are mainly limited to an increase of blood pressure. These effects are due to the 
stimulation of mineralocorticoid receptors by DOCA, giving rise to a 
hyperaldosteronism-like phaenotype. This induces constriction of the peripheral 
vessels, Na+ reabsorption in the nephron and passive water retention. Those 
changes lead to volume increase in blood vessels followed by pressure overload in 
the heart and responsive hypertrophic growth of the myocytes in order to preserve 
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cardiac output after activation of the renin-angiotension-aldosteron system among 
others (Mann et al. 2005, Francis 2001, Cohn et al. 2000).  
Both the cMI and the DOCA models have been used to evaluate the protective 
effects of PPARα expression levels and activities on ischaemia and hypertension 
induced heart failure. 
 
5.1 Heart failure in PPARα WT and KO mice 
 
The effects of physiological levels of PPARα expression and activity on the 
development of heart failure were investigated in WT mice by the comparison of 
placebo vs. sham groups. 
 
Effects of an abolished PPARα activity in heart failure were evaluated in PPARα KO 
mice, which are characterized by an insertion of a nonsense mutation in the ligand 
binding domain of the PPARα gene, resulting in a non-functional protein (Lee et al. 
1995).  
 
Survival of WT mice was twice as high as of KO mice after cMI induction, suggesting 
that KO mice are more sensitive to an ischaemic event by a permanent ligation of the 
LAD especially during the first week after surgery. The absence of PPARα activity 
seems to render these mice more susceptible to tissue injury. This increased 
vulnerability of hearts of KO mice was also seen in the morphological and functional 
changes induced by heart failure. These data are in agreement with literary findings 
showing an increased mortality after transverse aortic constriction in PPARα KO 
compared to WT mice (Smeets et al. 2008).   
 
Hypertrophy of the left ventricle, as reflected by an increase of the relative left 
ventricular weight, occurred in cMI and DOCA models (see 4.1.1 and 4.2.1). 
Pathological hypertrophy was due to the remodelling processes in the ventricle. 
Remodelling was accompanied by an increase of the expression of ANP and MyHCβ, 
which are markers for hypertrophy, and of Collagen 1A1 and TIMP1 which are 
markers for fibrosis and interstitial matrix remodelling in WT and KO placebo mice 
(see 4.1.3 and 4.2.4). The lack of a significant increase of collagen mRNA expression 
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levels, can be explained by the rapid turnover of collagen mRNA. Indeed, Chapmann 
et al. (1990) demonstrated that mRNA expression of collagen I and III was increased 
three days after abdominal aortic banding (pressure overload), but that levels after 
eight weeks almost returned to control levels. 
 
It is known from previous publications that myocardial infarction leads to a shift of the 
adult gene expression profile towards a foetal expression pattern, with increased 
ANP and MyHCβ mRNA expression levels (Ritter et al. 2003, Swynghedauw et al. 
1999), as well as increased fibrosis and extra cellular matrix regulating gene 
expression such as collagen type I and TIMP1 (Thomas et al. 1998, Cleutjens et al. 
1995). Additionally, our results, regarding hypertrophy of the left ventricle and 
expression of ANP, MyHCβ and TIMP1, are also in agreement with changes which 
are well known in DOCA models.  
 
Furthermore, DOCA treatment induced hypertrophic growth of the left ventricle and 
an increase of relative lung weight in our study. The increase of peripheral organ 
weight is induced by congestion of the peripheral blood in DOCA induced 
hypertension. There are hints that the development of hypertrophy and remodelling 
might, at least partially, be due to an interaction between PPARα and the renin-
angiotensin-aldosterone-system. It is well known that the renin-angiotensin-
aldosterone-system is activated by pressure overload. Myocardial ACE expression is 
increased in hypertrophied ventricles and results in increased Angiotensin II levels 
(Schunkert et al. 1990). Angiotensin II induces fibrosis of the right and left ventricles 
after pressure overload (Sun et al. 1997, Young et al. 1995, Robert et al. 1995, Brilla 
et al. 1990) probably by inducing endothelin 1 (Wollert et al. 1999). The interaction 
between the ACE system and PPARα activity will be more fully discussed later. 
 
Although hypertrophy and remodelling processes are seen in WT and KO mice in 
heart failure models, there are marked differences between the extent of remodelling 
occurring in these mice.  
 
Although sham WT and KO mice showed comparable relative heart weights, mRNA 
expression levels of MyHCβ, collagen 1A1 and TIMP1 were higher in sham KO 
compared to sham WT mice in both models. Additionally, although the morphological 
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changes were similar in both placebo WT and KO mice at the end of the studies, 
mRNA expression levels of hypertrophy and fibrosis markers were much more 
pronounced in placebo KO as in WT mice (see 4.1.3 and 4.2.4). Similar findings are 
reported by Smeets et al. (2008) in PPARα KO mice with transverse aortic 
constriction. PPARα KO mice subjected to aortic constriction showed higher mRNA 
expression levels of e.g., ANP and collagen 1 when compared to WT mice. 
Additionally, osteopontin, an important marker for interstitial matrix remodelling, was 
noticeably increased in placebo WT and KO mice. But the increase of osteopontin 
mRNA expression levels between placebo and sham mice was much higher in KO 
compared to WT mice (18 and 8 fold in KO mice vs. 3 fold in WT mice in the cMI and 
DOCA studies, respectively). This suggests a more pronounced matrix remodelling in 
PPARα KO compared to WT mice. These data further document the higher 
susceptibility of PPARα KO mice towards hypertrophy, fibrosis and interstitial matrix 
regulation in heart failure and the importance of basal PPARα expression levels for 
heart protection. 
 
In summary, basal PPARα activity seems to be protective in heart failure and 
abrogated PPARα activity renders mice more susceptible to heart failure.  
 
Remodelling processes during heart failure resulted in a worsening of cardiac 
function, which was assessed by haemodynamic measurements in WT and KO mice.  
The degree of deterioration of cardiac function was tremendously higher in PPARα 
KO compared to WT mice in both models. 
 
In sham KO mice, haemodynamics, except for diastolic function (LVEDP), were 
comparable to sham WT mice in the cMI and DOCA models. LVEDP was lower in 
KO compared to WT mice in both studies. Those changes in LVEDP are consistent 
with data reported by Loichot et al. (2006) showing that PPARα KO mice had an 
alteration of cardiac contractile performance (left ventricular fractional shortening 
measured by echocardiography) under basal conditions without change in blood 
pressure nor heart rate. 
 
Haemodynamics showed a further deterioration of systolic and diastolic function in 
KO mice compared to WT mice. In the cMI study, systolic blood pressure and 
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contractility further decreased, LVEDP and the relaxation time further increased in 
PPARα KO compared to WT mice. In the DOCA study, haemodynamic changes 
were not as marked as in the cMI study. One explanation could be the shorter 
duration of the DOCA study and the lower strength of the stimulus used for the 
induction of heart failure. It is also known that haemodynamic effects, apart from 
increased systolic blood pressure, are not always observed after DOCA treatment in 
rats (Iglarz et al. 2003).  
 
The results of our studies add to several previous publications, showing increased 
sensitivity to heart failure in PPARα KO compared to WT mice. It has been showed in 
an ischaemia / reperfusion study, that hearts from PPARα KO mice were more 
susceptible for myocardial dysfunctions (longer time of recovery and lower developed 
force) than those from WT mice and that the beneficial effects of fenofibrate 
treatment were lost in KO mice (Tabernero et al. 2002). Similarly, Yue et al. (2003) 
demonstrated greater infarct sizes in PPARα KO mice hearts after ischaemia / 
reperfusion than in WT mice hearts. It also seems that PPARα KO mice had reduced 
systolic performance in echocardiographic measurements without changes in heart 
rate and blood pressure (Loichot et al. 2006). Furthermore, isolated perfused hearts 
from these mice had reduced developed force at basal levels and after β-adrenergic 
stimulation compared to WT mice and these effects were associated with myocardial 
fibrosis. Finally, it has been reported that PPARα KO mice had reduced systolic 
performance without ventricular dilatation in echocardiography and significant 
cardiomyocyte hypertrophy in histological investigations (Guellich et al. 2007). 
Markers of oxidative damage were increased in PPARα KO mice hearts. These data 
indicate that functional PPARα seems to be required to protect and preserves 
contractile function in cardiac muscle. 
 
5.2 Heart failure under treatment with a PPARα agonist in 
WT and KO mice 
 
Our next step was to evaluate the effects of activation of PPARα by a PPARα 
agonist, fenofibrate, on heart failure.  
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Enhancement of PPARα activity was determined by treatment of WT and KO mice 
with fenofibrate. Increased PPARα activity might have beneficial effects in heart 
failure by amelioration of energy supply for the myocardium and / or reduction of 
heart remodelling and improvement of function (Finck 2007 and Schiffrin 2005).  
 
Increase of PPARα activity levels by fenofibrate induced an almost two fold increase 
of the liver weight (see 4.1.1 and 4.1.2) in WT but not in KO mice. This is due to 
peroxisome proliferation with hepatocellular hypertrophy and hyperplasia with final 
hepatomegaly, a known effect of PPARα agonists in rodents, but not in humans 
(Kliewer et al. 2001).  
 
Treatment with fenofibrate decreased relative left ventricular and heart weight in WT 
but not in KO mice in cMI and DOCA models. This decrease of the cardiac 
hypertrophy was closely connected to a significant decrease of expression levels of 
hypertrophy markers, ANP and MyHCβ in WT mice.   
Effects of fenofibrate on pressure overload induced hypertrophy are controversial. 
Iglarz et al. (2003) and Ogata et al. (2004) did not report any improvement of relative 
left ventricular weight after fenofibrate treatment in DOCA rats, whereas Lebrasseur 
et al. (2007), Irukayama-Tomobe et al. (2004), Rose et al. (2007) and Li et al. (2008) 
showed significant improvement of relative left ventricular weight after treatment with 
fenofibrate in mice with aldosterone induced hypertension, rats with aortic banding or 
spontaneous hypertensive rats (SHR), respectively. In parallel to the prevention of 
heart hypertrophy by fenofibrate, Lebrasseur et al. (2007) also showed improved 
MyHCβ mRNA expression levels after treatment with a PPARα agonist.  
In contrast, effects of a PPARα agonist on cardiac remodelling after ischaemia-
induced heart failure has not yet been published, having first been evaluated in this 
study.  
 
Fibrosis gene expression levels, such as collagen 1A1 and TIMP-1 were improved in 
WT mice by treatment with the PPARα agonist, although this effect was not as 
marked in the DOCA study as in the cMI study. This is in agreement with data from 
Ogata et al. (2002, 2004), who showed a decrease of fibrosis after treatment with 
fenofibrate in pressure overloaded rats.  
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Furthermore, the PPARα agonist improved mRNA expression levels of osteopontin, 
a marker of interstitial matrix remodelling, in cMI WT mice. It has been reported that 
osteopontin expression is increased in the heart during hypertrophy and heart failure 
in a banding study with mice (Xie et al. 2004). It has also been showed that treatment 
of macrophages with fibrates inhibited osteopontin expression through negative 
cross-talk with AP-1 dependent trans-activation of the osteopontin promoter 
(Nakamachi et al. 2007). Finally, the down regulation of osteopontin expression after 
treatment with fenofibrate in Dahl-salt sensitive rats has been reported (Ichihara et al. 
2006). 
 
Our data provide evidence that treatment with a PPARα agonist has antihypertrophic 
and antifibrotic effects and modulates the interstitial matrix in WT mice in ischaemia 
and hypertension induced heart failure. 
 
Remodelling processes during heart failure resulted in a worsening of cardiac 
function, which was assessed by haemodynamic measurements in WT and KO mice. 
Whereas increase of PPARα activity by fenofibrate resulted in an improvement of 
cardiac function and amelioration of hypertrophy and fibrosis.  
 
In the cMI study, treatment with the PPARα agonist tended to improve LVEDP and 
the relaxation constant tau and significantly improved contractility. No effects were 
observed in KO mice. 
From literary sources it is known that PPARα agonists improve myocardial contractile 
dysfunction after ischaemia / reperfusion in WT mice, and that those effects are 
abolished in PPARα KO mice (Yue et al. 2003, Tabernero et al. 2002). Li et al. 
(2008) and Ogata et al. (2004) showed improved diastolic functions in pressure 
overload induced heart failure models after treatment with fenofibrate. Our data 
provides evidence that cardiac dysfunction can also be improved by treatment with 
fenofibrate in ischaemia induced heart failure. 
In the DOCA study, haemodynamic parameters were not as deteriorated as seen in 
the cMI study and no improvement with fenofibrate was detected. As already 
discussed, the study duration might have been too short to show the effects of 
PPARα agonists on haemodynamics or the concentration of the compounds was too 
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low, as suggested by the lack of PDK4 gene induction in the myocardium, to have 
had a sufficient effect. 
 
Furthermore, DOCA treatment induces an increase of systolic blood pressure in rats, 
an effect also observed in WT and KO mice. Treatment with fenofibrate did not 
improve blood pressure. This is in agreement with studies performed in DOCA 
treated rats by Iglarz et al. (2003) or Aldosterone treated mice by Lebrasseur et al. 
(2007). In contrast, Zhou et al. (2008) reported that treatment of WT mice with DOCA 
salt induced hypertension with clofibrate, a PPARα agonist, could significantly reduce 
mean arterial blood pressure by increasing expression of 20-hydroxyeicostetraenoic 
acid (20-HETE). These data suggest that mechanistical differences between various 
fibrates and their in vivo activity exist.  
 
In summary, abrogation of PPARα activity renders mice much more susceptible 
towards hypertrophy, fibrosis and inflammation and boosts deterioration of heart 
function in hypertension and ischaemia induced heart failure. Basal PPARα activity 
can attenuate heart failure and increase of PPARα activity back to normal levels 
seems to further improve the protection of the heart. 
 
5.3 Cardiorenal syndrome 
 
Heart failure is often associated with kidney dysfunction, called the cardiorenal 
syndrome. The cardiorenal syndrome is associated with a high mortality (Heywood 
2004). The glomerular filtration rate of heart failure patients is an important 
determinant of survival (Dries et al. 2000). Furthermore, an increase in serum 
creatinine levels is a very specific marker for poor prognosis (Smith et al. 2003, 
Gottlieb et al. 2002). 
The causes of heart failure associated renal insufficiency are diverse. Decreased 
renal perfusion, as induced by hypovolemia, vasoconstriction or hypotension (low 
cardiac output), but also high central venous pressure are important factors for renal 
dysfunction (Firth et al. 1988) resulting in inflammatory and remodelling processes. 
The simultaneous protection of heart and kidney would, therefore, be beneficial in 
heart failure patients. 
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In the DOCA study we evaluated the effects of PPARα expression levels on kidney 
protection. Urine volumes were comparable within sham WT and KO mice, showing 
comparable renal functions in these animals. However, the protein / creatinine ratio 
was increased in KO as compared to WT mice. This might be an early indication that 
basal PPARα activity is needed for normal kidney function even without the 
challenge of heart failure induction. 
 
Nephrectomy of one kidney in the DOCA model induced a successive hypertrophy of 
the remaining right kidney in WT and KO mice. This is in agreement with literary 
sources (Hayslett 1979). At the end of the DOCA study, diuresis of placebo WT and 
KO mice resulted in increased urine volumes, protein / creatinine ratios, Na+ / K+ 
ratios and decreased urea concentration in the urine of mice compared to their 
respective sham groups. These effects are in accordance with well established data 
in DOCA studies in rats (Newaz et al. 2005, Matsumura et al. 1999, Stumpe et al. 
1970).  
But, similarly to the heart failure data, KO mice showed enhanced deterioration of 
kidney function: urine volumes, protein / creatinine ratios and Na+ / K+ ratios were 
much more pronounced and urea further decreased in KO compared to WT mice. 
This is in agreement with a study by Newaz et al. (2005) which showed a higher 
increase of urine protein content in PPARα KO compared to WT mice after DOCA 
treatment. Additionally, Park et al. (2006) reported that PPARα KO mice had more 
severe diabetic nephropathy compared to WT mice. 
 
In summary, PPARα activity is not only important for the protection of the heart, but 
also for kidney function in ischaemia and hypertension induced heart failure. 
 
5.4 Mechanisms for the protective effects of PPARα activity 
 
There are several possible explanations for the shades of protective effects by 
different PPARα activity levels. One explanation is based on the protective role of 
PPARα in cardiac remodelling, independently from lipid modulation and fuel 
utilization in the heart. 
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PPARα has an important function in cardiac remodelling by direct modulation of 
interstitial matrix remodelling, fibrosis and hypertrophy through the activation or 
inhibition of different genes or signalling pathways, like Activator protein-1, 
Endothelin-1, ACE or the NFκB pathways (Newaz et al. 2005, Ogata et al. 2004 and 
2002, Iglarz et al. 2003). This was also shown in our studies by the modulation of 
genes involved in hypertrophy, like MyHC-β or matrix remodelling, like TIMP-1 and 
osteopontin. 
One example for the interaction of PPARα with pathways involved in hypertrophy and 
fibrosis is the interplay of PPARα with the renin-angiotensin-aldosterone system. 
In the cMI and DOCA studies, treatment of WT mice with fenofibrate resulted in 
comparable or even better protection from hypertrophy and fibrosis as well as 
improvement of cardiac functions than the treatment with the ACE inhibitor ramipril. 
Surprisingly, ramipril could not protect the heart from hypertrophy, fibrosis and 
deterioration of haemodynamic function in cMI KO mice. Only the reduction of blood 
pressure was still observed. These data suggest that the beneficial effects of ACE 
inhibitors, which are recommended by the European Society of Cardiology in the 
standard therapy of heart failure patients (ESC guidelines 2008), depend at least 
partially on PPARα activity in ischaemia induced heart failure. Restoration of PPARα 
activity in heart failure patients might, therefore, even improve ACE inhibitor related 
protection of hearts from further deterioration in patients. 
The interaction between PPARα and ACE inhibitors has also been described in 
literature. It has been shown that enalapril upregulates the PPARα expression in 
mice with angiotensin II induced atherosclerosis, resulting in anti-inflammatory effects 
(downregulation of NFκB, ICAM-1, VCAM-1) (Da Cunha et al. 2005). 
It has also been reported that overexpression of angiotensinogen in the myocardium 
induces the down regulation of PPARα activity, resulting in a reduction of the fatty 
acid oxidation pathway in mice (Pellieux et al. 2006). Additionally, the PPARα 
response element has been identified in the renin gene of spontaneous hypertensive 
rats (Di Nicolantonio et al. 1998). 
 
The interaction between PPARα and the renin-angiotensin-aldesterone pathway is 
only one example of several pathways which might be involved in protection from 
failure development by PPARα. 
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A further explanation for the protective effects by PPARα is based on the energy 
status and the energy utilization of the heart during heart failure. The healthy 
myocardium obtains 60-90 % of its energy from fatty acid oxidation (FAO) (Huss et 
al. 2004). Inherited defects in many key enzymes of FAO are associated with 
cardiomyopathy and sudden death in children and young adults (Kelly et al. 1994) 
and cardiac hypertrophy and failure are accompanied by a switch from fatty acids to 
glucose utilization and PPARα down regulation (Finck 2007). PPARα is highly 
expressed in tissues with elevated capacity for FAO, like liver, kidney and heart, and 
it is an important transcriptional regulator of myocardial energy and lipid homeostasis, 
through modulation of key enzymes of the FAO pathway such as medium chain 
acetyl coenzyme A dehydrogenase (MCAD) or carnitin palmitoyl transferase-1 (CPT-
1) (Finck, 2007 and Schiffrin, 2005). The absence of PPARα activity results in a 
complete change of the fuel utilization and energy supply in the heart.  
PPARα KO mice have decreased basal levels of enzymes involved in fatty acids β-
oxidation, like carnitine palmitoyl transferase-1 (CPT-1) or medium chain acyl-
coenzyme A dehydrogenase (MCAD) (Aoyama et al. 1998). This was also confirmed 
in our studies. Indeed expression of pyruvate dehydrogenase kinase, isozyme 4 
(PDK4) was reduced (see 4.1.3 and 4.2.4) in KO compared to WT mice in the DOCA 
and cMI experimental settings. Furthermore KO mice had similar plasma levels of 
triglycerides, but increased plasma levels of total cholesterol, HDL and LDL 
compared to WT mice. Those increased lipid plasma levels are due to decreased 
expression of fatty acids-β oxidation related genes because of the lack of PPARα 
activity and an accumulation of lipids (Ahmed et al. 2007, Francis et al. 2002, Peters 
et al. 1997). 
Several reports indicate that the capacity of PPARα KO mice for constitutive 
myocardial β-oxidation is markedly reduced compared to WT mice and their mRNA 
expression levels of fatty acid transporters are decreased (Watanabe et al. 2000). At 
last, myocardium of PPARα KO mice had decreased ATP concentration after 
exposure to stress (starvation and high temperature).  
It has also been demonstrated that cardiac PPARα gene expression falls and its 
activity is altered at the posttranscriptional level via the extracellular signal-regulated 
kinase mitogen-activated protein kinase pathway during hypertrophic growth, and 
that the decrease in PPARα activity was followed by a decrease in muscle carnitin 
palmitoyl transferase-1 (mCPT-1) (Barger et al. 2000). 
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It seems that an energy profile with decreased fatty acid and increased glucose 
utilization in isolated hearts of PPARα KO mice is sufficient for sustaining normal 
energy metabolism and contractile function at baseline but that the metabolic reserve 
is depleted at high workload, which induces functional deterioration (Luptak et al. 
2005). Similarly, it has been showed that glucose oxidation rates are significantly 
higher and FAO significantly lower in PPARα KO mice compared to WT mice during 
pre- and postischaemic perfusions (Sambandam et al. (2006). Additionally, Gélinas 
et al. (2008) demonstrated an impaired capacity to withstand a rise in preload, in 
isolated working hearts from PPARα KO mice, because of a restricted reserve to 
enhance glycolysis when the energy demand is increased. 
All together these data suggest that the lack of PPARα results in decreased FAO in 
the heart and deteriorated heart function. Restoring PPARα activity should therefore 
be beneficial in cardiac energy supply and function. 
 
However, effects of PPARα agonist on the energy supply of the heart are 
controversial.  
On the one hand it has been reported that reactivation of PPARα in early stages of 
heart failure development could be deleterious by accumulating lipids in the 
myocardium and worsening cardiac dysfunction. Some data showed that reactivation 
of PPARα with a PPARα agonist, results in severe depression of cardiac power and 
efficiency in the hypertrophied heart because of the prevention of substrate switching 
in an aortic banding study in rats (Young et al. 2001). To maintain its contractile 
function, the hypertrophied heart decreases its reliance on fatty acids as a major 
substrate for ATP generation while increasing its reliance on glucose as a fuel, 
mainly through regulation of PPARα. However, this study only lasted one week and 
the long term down regulation of PPARα and FAO may contribute to energy 
starvation (lower ATP production through Glucose oxidation) of the myocardium and 
cardiac lipotoxicity (storage of lipid in the myocyte followed by apoptosis). The 
process which at first appears to be adaptive may turn out maladaptive in the longer 
term (Balakumar et al. 2007, Ogata et al. 2004). Furthermore, it has been shown that 
PPARα agonists prevent cardiac lipotoxicity in hypertension induced heart failure 
(Ogata et al. 2004). 
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On the other hand, PPARα agonists, such as fenofibrate, restore FAO and reduce 
glycolysis in heart in preclinical models, resulting in protective effects for heart failure 
development.  
An ischaemia / reperfusion study in PPARα WT and KO mice showed that treatment 
with a PPARα agonist reversed the decrease of myocardial FAO enzyme activity and 
the increased serum levels of free fatty acids in WT mice but not KO mice and that 
those effects are associated with improved contractile function in those mice (Yue et 
al. 2003). Furthermore, it has been reported in a study of lipotoxic cardiomyopathy in 
mice, that treatment with fenofibrate reduced the high plasma and myocardial 
triglyceride levels and increased the low ATP content of the heart and that those 
effects were also accompanied by an improved left ventricular function and survival 
of mice (Asai et al. 2006). 
 
This study shows that reactivation of PPARα by fenofibrate is beneficial in heart 
failure by reducing triglycerides levels and improving cardiac function. Furthermore 
fenofibrate had anti-hypertrophic and anti-fibrotic effects on the left ventricle, which 
further contribute to the improvement of cardiac function.  
 
So far these protective effects by fibrates have not been described in patients with 
heart failure. In patients, fenofibrate is used as a lipid lowering drug, which decreases 
triglycerides and LDL cholesterol and increases HDL cholesterol (Fruchart et al. 
2006, Staels et al. 1998). The protective effect on heart failure development in 
preclinical heart failure models has never been evaluated in clinical studies with heart 
failure patients. Clinical studies using PPARα agonists in patients had lipid lowering 
endpoints and patients with heart failure were excluded from the trials.  Additionally, 
no hint of a protective effect have been reported from clinical studies determining lipid 
modulation in patients with heart diseases. This discrepancy between preclinical and 
clinical data might be due to the dose of fenofibrate used in animal models and 
patients and the tissue distribution of fenofibrate. In preclinical models (including our 
studies) dosages of 80 mg/kg/day of fenofibrate were used. The human daily dose is 
300 mg (~4 mg/kg/day). It might well be that dosages of the weak PPARα agonist 
fenofibrate which are suitable for lipid modulation in patients are not sufficient for 
protection of the heart. Additionally, fenofibrate is tremendously enriched in liver 
compared to heart (Balfour et al. 1990) in animals and patients, meaning that the 
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concentration of fenofibrate in the heart might be too low for the induction of PPARα 
regulated genes involved in slowing of remodelling processes and probably not 
adequate for heart failure protection in patients.  
The distribution of a PPARα compound, which would be comparable in liver and 
heart, could open up the opportunity to reach drug tissue levels which might be 
suitable to delay heart failure development in patients. 
 
In summary, one important factor for the protective effects of PPARα in heart failure 
development might be the modulation of fuel (FAO / glucose oxidation) utilization in 
the heart. Reduction or abolishment of PPARα activity leads to depletion of metabolic 
reserves and energy allocation especially under high workload resulting in 
morphological and functional deterioration of the heart. Whereas restoration of 
PPARα activity leads to normalization of energy supply and protection of heart 
function. Another important factor for the protective effects of PPARα in heart failure 
might be the effects on cardiac remodelling with antihypertrophic and antifibrotic 
effects as well as regulating interstitial matrix. 
 
Further investigations are needed to completely elucidate the complex interplay 
between PPARα activity, fuel utilization and direct antihypertrophic and antifibrotic 
effects in the heart.  
 
5.5 Conclusion 
 
In conclusion, this study shows that the level of PPARα expression and activity 
determines the susceptibility of mice towards heart failure. Remodelling and 
functional restriction is much more pronounced in PPARα KO compared to WT mice. 
PPARα expression is needed as an important protective factor to attenuate heart 
failure. The absence of PPARα activity renders KO mice pronouncedly more 
sensitive for heart failure and worsens remodelling processes and heart function. On 
the contrary, treatment with PPARα agonists to normalize PPARα activity, which is 
reduced in heart failure, ameliorates heart failure in ischaemia and pressure overload 
induced heart failure by mechanisms involved in energy homeostasis and/or anti 
matrix remodelling, antifibrotic and antihypertrophic processes. 
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The normalization of PPARα activity by PPARα agonists should, therefore, be 
beneficial in patients and merits further clinical investigations.  
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6. Summary 
 
Heart failure is a progressive clinical syndrome which is characterized by the inability 
of the heart to pump or fill with a sufficient amount of blood through the systemic 
circulation. One receptor, which seems to be involved in the remodelling processes 
accompanying the progression of heart failure, is the peroxisome proliferator-
activated receptor alpha (PPARα).  Indeed, it seems that PPARα is downregulated in 
patients with heart failure and has antihypertrophic and antifibrotic effects on the 
myocardium. Thus, the aim of this study was to investigate the role of PPARα in the 
remodelling processes related to heart failure, in models of ischaemia (chronic 
myocardial infarction model) and hypertension (deoxycorticosterone acetate / DOCA 
salt model) induced heart failure, the two most important causes of heart failure 
development in patients. To this end, the effects of abrogation of PPARα activity in 
knock-out (KO) mice were compared to normal activity in wild-type (WT) mice and 
activation of PPARα by the PPARα agonist fenofibrate (80 mg/kg/d) in the two 
aforementioned models. Furthermore the treatment with fenofibrate was compared to 
a standard therapy with the ACE inhibitor ramipril (10 mg/kg/d). 
Left ventricular function was evaluated via invasive haemodynamic measurements 9 
weeks after coronary ligation and 6 weeks after beginning of DOCA treatment. Left 
ventricular expression profiles of hypertrophy and fibrosis genes were analyzed by 
real-time PCR. At last, lipid profiles in the plasma were measured. In the DOCA 
model, kidney function was additionally measured by diuresis.  
PPARα KO mice with ischaemia induced heart failure showed a significantly reduced 
survival compared to WT mice after surgery (60 % compared to 80%). 
Both models resulted in hypertrophy of the left ventricle which was also reflected in 
the biomarker analysis. For both models markers of hypertrophy and fibrosis were 
enhanced compared to Sham mice. Furthermore KO mice showed higher levels of 
myosin heavy chain β (MyHCβ), collagen and tissue inhibitor of metalloproteinase 1 
(TIMP1) than WT mice (almost 3 fold increase). On the contrary, treatment with 
fenofibrate or ramipril could prevent increases of the biomarkers in WT mice but not 
in KO mice. 
In both models, worsening of morphology was also reflected in the cardiac function. 
Although baseline haemodynamics were similar in sham WT and Sham KO mice, 
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they were significantly differing between the treated WT and KO mice. Indeed, 
contractility (LVdp/dtmax) and relaxation (LVdp/dtmin and relaxation constant tau) were 
more impaired in KO compared to WT mice. Similarly to the morphology, KO mice 
showed more impaired cardiac function than WT mice and treatment with fenofibrate 
and ramipril partially restored ventricular function in WT but not KO mice. 
In conclusion, this study shows that the level of PPARα expression and activity 
determines the susceptibility of mice towards heart failure development. The absence 
of PPARα activity renders KO mice tremendously more sensitive for heart failure 
development and worsens remodelling processes and heart function. On the 
contrary, treatment with fenofibrate to normalize PPARα activity, which is reduced in 
heart failure, ameliorates heart failure in ischaemia and pressure overload induced 
heart failure by mechanisms involved in energy homeostasis and/or anti matrix 
remodelling, antifibrotic and antihypertrophic processes. 
The normalization of PPARα activity by PPARα agonists should, therefore, be 
beneficial in patients and is of value for further clinical investigations.  
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7. Zusammenfassung 
 
Herzinsuffizienz ist ein progressives klinisches Syndrom, charakterisiert durch das 
Unvermögen des Herzens den Kreislauf mit genügend Blut zu versorgen.  Ein 
Rezeptor, der an den Herzinsuffizienz begleitenden Remodelling Prozessen, beteiligt 
zu sein scheint, ist der „peroxisome proliferator-activated receptor alpha (PPARα). In 
der Tat, scheint der PPARα bei Patienten mit Herzinsuffizienz herunter reguliert zu 
sein und soll außerdem antihypertrophe und antifibrotische Wirkungen auf das 
Myokard haben. Ziel dieser Studie war es daher, die Rolle von PPARα bei den mit 
Herzinsuffizienz assoziierten Remodelling Prozessen mit Hilfe einer durch Ischämie- 
(chronischer Myokardinfarkt Modell) und Hypertonie- (deoxycorticosterone Acetate / 
DOCA Salz Modell) induzierten Herzinsuffizienz, zu untersuchen. Zu diesem Zweck 
wurden die Effekte der Aufhebung der PPARα Aktivität bei knock-out (KO) Mäusen 
mit der normalen Aktivität in Wildtyp (WT) Mäusen und Aktivierung von PPARα durch 
den PPARα Agonisten, Fenofibrate (80 mg/kg/d), in den zwei oben erwähnten 
Modellen, verglichen. Zusätzlich wurde die Fenofibratebehandlung mit einer 
Standardtherapie mit einem ACE Hemmer, Ramipril (10 mg/kg/d), verglichen. 
Die linksventrikuläre Funktion wurde 9 Wochen nach Ligation der Koronararterie oder 
6 Wochen nach Anfang der DOCA Behandlung mittels invasiver hämodynamischer 
Messungen bewertet. Genexpression für Hypertrophie und Fibrose wurde mittels 
real-time PCR Analyse gemessen. Schließlich wurden Plasma Lipidprofile ermittelt. 
Zusätzlich wurde die Nierenfunktion mittels Diurese in dem DOCA Modell bestimmt. 
PPARα KO Mäuse mit durch Ischämie induzierter Herzinsuffizienz zeigten signifikant 
reduzierte Überlebensraten nach der Operation im Vergleich zu den WT Mäusen (60 
% im Gegensatz zu 80%). 
Beide Modelle resultierten in einer Hypertrophie des linken Ventrikels, was durch 
eine Gewichtsermittlung und Biomarkeranalyse gezeigt werden konnte. In beiden 
Modellen, sowohl bei WT als auch bei KO herzinsuffizienten Mäusen verglichen zu 
deren respektiven scheinoperierten Tieren, konnte eine zwei- bis zehnmal erhöhte 
Genexpression für Hypertrophie und Fibrose nachgewiesen werden. Zusätzlich, 
zeigten KO Mäuse eine höhere Genexpression für myosin heavy chain β (MyHCβ), 
collagen und tissue inhibitor of metalloproteinase 1 (TIMP1) als WT Mäuse (fast 
3fache Erhöhung). Die Behandlung mit dem ACE Hemmer Ramipril konnte die 
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Erhöhung der Biomarker sowohl in der Gruppe der WT, als auch in der Gruppe der 
KO Mäuse verhindern, während Behandlung mit dem PPARα Agonist Fenofibrate, 
wie erwartert,  nur einen Effekt bei den WT, nicht aber bei den KO Mäusen, zeigte. 
In beiden Modellen, wurde die Verschlechterung der Morphologie ebenso in einer 
Verschlechterung der Herzfunktion wiedergespiegelt. Obwohl die Basalwerte der 
Hämodynamikmessungen vergleichbar zwischen scheinoperierten WT und KO 
Tieren waren, wurden große Unterschiede in den anderen Gruppen festgestellt. 
Kontraktilität (LVdp/dtmax) und Relaxation (LVdp/dtmin und Relaxationskonstante tau) 
waren verschlechtert in der Gruppe der KO Mäuse verglichen zu der der WT Mäuse 
(etwa 20%). Ähnlich zu der Morphologie, zeigten KO Mäuse eine verschlechterte 
Herzfunktion verglichen mit der der WT Mäuse.  Wiederum konnte die Behandlung 
mit Ramipril die Herzfunktion der WT und KO Mäuse teilweise wiederherstellten, 
während eine Behandlung mit Fenofibrate lediglich bei den WT Mäusen,  nicht aber 
bei den KO Mäusen eine Verbesserung ermöglichte.  
Schließlich zeigt diese Studie, dass die Expressions- und Aktivitätshöhe von PPARα 
die Empfindlichkeit der Mäuse gegenüber Herzinsuffizienzentwicklung bedingt. Der 
Mangel an PPARα Aktivität verursacht eine höhere Empfindlichkeit der KO Mäuse 
gegenüber einer Herzinsuffizienz und eine Verschlechterung der damit assoziierten 
Remodellingsprozesse und der Herzfunktion. Im Gegensatz dazu führt eine 
Behandlung mit Fenofibrate zur Wiederherstellung der mit einer Herzinsuffizienz 
einhergehenden herabgesetzten PPARα Aktivität. Im Zuge dessen verbessert 
Fenofibrate eine durch Ischämie und Hypertonie induzierte Herzinsuffizienz. Seine 
Wirkung erzielt es bei Mechanismen involviert in Energie Homöostase und / oder  
Matrix Remodelling, antifibrotische- und antihypertrophe Prozesse. 
Zusammenfassend kann man sagen, dass eine Normalisierung der PPARα Aktivität 
bei PPARα Agonisten sehr nützlich bei Patienten mit Herzinsuffizienz ist und  
unbedingt Inhalt weiterer  klinischer Untersuchungen sein sollte. 
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12. Appendix 
 
12.1 Appendix to “Material” 
 
12.1.1 Chemicals 
 
 Chemicals used for the surgery and necropsy 
 
Bepanthen® (Panthenol) Bayer Vital, Leverkusen, Germany 
Cutasept F skin disinfectant Bode Chemie, Hamburg, Germany 
Ethanol Merck, Darmstadt, Germany 
Isoflurane CP CP Pharma, Burgdorf, Germany 
Isotonic NaCl solution 0.9 Fresenius Kabi, Bad Homburg, Germany 
Nebacetin Powder Spray 
 
Astellas Pharma GmbH, Munich, 
Germany 
Phosphate Buffered Saline (PBS) 
 
Sigma Aldrich Chemie GmbH. Steinheim, 
Germany 
Sodium chloride (NaCl) for analysis Merck, Darmstadt, Germany 
Solutol BASF, Ludwigshafen, Germany 
 
12.1.2 Equipment 
 
Animal scale Mettler PM 2000 
 
Mettler Instrumente GmbH, Gießen, 
Germany 
Cold light lamp KL 1500 LCD Schott, Mainz, Germany 
Electronic digital caliper 0-150mm Promat, Lübeck, Germany 
Eppendorf tubes 1.5 ml Eppendorf, Wesseling-Berzdorf, Germany 
Heating panel In house production 
Isoflurane Vapor 19.3 Drägerwerk AG, Lübeck, Germany 
Leukosilk® adhesive tape, 1.25 and 2.5 
cm width 
BSN medical GmbH, Hamburg, Germany 
 
Metabolic cages Tecniplast, Buguggiate, Italy 
Narcosis box In house production 
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Narcosis mask In house production 
Neolus® Needle 23G and 27G Terumo® Europe N.V., Lewen, Belgium 
Pipettes and furnitures Eppendorf, Wesseling-Berzdorf, Germany 
Precision scale Mettler PM 400 
 
Mettler Instrumente GmbH, Gießen, 
Germany 
Semperguard disposable latex gloves 
 
Semperit technische Produkte GmbH & 
Co KG, Vienna, Austria 
Shaver contura Wella AG, Darmstadt, Germany 
S-Monovette® - Needle 20G 11/2, 
85.1160 
Sarstedt, Nümbrecht, Germany 
 
S-Monovette® 1.2ml LH (Lithium-
Heparin), 06.1666.001 
Sarstedt, Nümbrecht, Germany 
 
Stereo Lupe Leica M651 Leica, Wetzlar, Germany 
Table vacuum cleaner "Wet 7 & Dry" 
 
SEVERIN Elektro GmbH, Sundern, 
Germany  
Tuberculin syringe 1ml 
 
Codan Vertrieb GmbH & Co KG, Lensahn, 
Germany 
Tubus for intubation In house production 
Ventilation pump minivent type 585 Hugo Sachs electronics, March, Germany 
 
12.1.3 Surgical instruments and threads 
 
Curved anatomical forceps: 12-503-10 Aesculap by B. Braun, Tuttlingen, Germany  
Curved dissecting forceps: BD 257 Aesculap by B. Braun, Tuttlingen, Germany  
Dissecting forceps: BD 23 Aesculap by B. Braun, Tuttlingen, Germany  
Eye scissors: OC 500 Aesculap by B. Braun, Tuttlingen, Germany  
Eyelid spreader: 17003-03 FST, Bad Oeynhausen, Germany 
Metzenbaum scissors: 11-248-11 Martin GmbH, Tuttlingen, Germany 
Micro suture tying forceps: FD 281 Aesculap by B. Braun, Tuttlingen, Germany  
Mosquito clamp: BH 104 Aesculap by B. Braun, Tuttlingen, Germany  
Needle holder Barraquer – Troutmann: 
20-299-11 
Martin GmbH, Tuttlingen, Germany 
 
Needle holder Castroviejo: 20-311-14 Martin GmbH, Tuttlingen, Germany 
Ethibone 5/0 thread (1 metric,V-18, Ethicon by Johnson and Johnson, St.-
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6913H). Stevens-Woluwe, Belgium 
Prolene 6/0 thread (0.7 metric, TF-6, 
EH7814H) 
Ethicon by Johnson and Johnson, St.-
Stevens-Woluwe, Belgium 
Vicryl 6/0 thread (0.7 metric, TF1, 
V234H) 
Ethicon by Johnson and Johnson, St.-
Stevens-Woluwe, Belgium 
 
12.2 Appendix to “Methods” 
 
12.2.1 Diagnostic kits used for the urine analysis 
 
CREA Creatinine: Jaffé, kinetic- test, the centrifuged urine is diluted.  
Test kit Messrs. Roche Diagnostics GmbH using Hitachi 717 or 704 
K Potassium:  flame photometric assay with lithium reference line, using 
flame photometer EFUX 5057, distribution Messrs. Eppendorf- Netheler- 
Hinz GmbH 
Na Sodium:  flame photometric assay with lithium reference line, using flame 
photometer EFUX 5057, distribution Messrs. Eppendorf- Netheler- Hinz 
GmbH 
PROT Total Protein:  modified according to Richterich, R., "Urin - Protein: Biuret - 
Methode", in: Richterich, R., Klinische Chemie, 2nd Edition, p.533 - 535, 
Akademische Verlagsgesellschaft, Frankfurt (1968) 
UREA Urea: enzymatic UV test, the centrifuged urine is diluted. 
Test kit Messrs. Roche Diagnostics GmbH using Hitachi 717 or 704 
 
12.2.2 Diagnostic kits used for the lipid analysis 
 
Cholesterol: enzymatic colour test of 100µl plasma. 
Cartridge COBAS INTEGRA Cholesterol Gen.2 (Roche Diagnostics) 
Triglyceride: enzymatic colour test of 100µl plasma. 
Cartridge COBAS INTEGRA Triglycerides (Roche Diagnostics) 
LDL: enzymatic colour test of 100µl plasma. 
Cartridge COBAS INTEGRA LDL-Cholesterol plus 2nd generation 
(Roche Diagnostics) 
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HDL: enzymatic colour test of 100µl plasma. 
Cartridge COBAS INTEGRA HDL-Cholesterol plus 3rd generation 
(Roche Diagnostics) 
 
12.3 Appendix to “Results” 
 
12.3.1 cMI model 
 
Table 1: Infarct scores of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 0.0 ± 0.0 AU 0.0 ± 0.0 AU 
Placebo 3.2 ± 1.3 AU 3.6 ± 1.2 AU 
Fenofibrate 3.4 ± 1.1 AU 3.1 ± 1.2 AU 
Ramipril 3.0 ± 1.0 AU 4.0 ± 1.1 AU * 
AU: arbitrary units; n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05 vs respective WT group; unpaired t-
test 
 
Table 2: Body weight of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 30.0 ± 0.8 g 26.1 ± 0.5 g 
Placebo 29.3 ± 0.6 g 25.3 ± 0.9 g 
Fenofibrate 29.8 ± 0.9 g 24.7 ± 0.6 g 
Ramipril 30.3 ± 0.8 g 24.4 ± 0.7 g 
n= 16 (WT), 8 (KO); mean ± SEM 
 
Table 3: Relative heart weight of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 4.3 ± 0.0 mg/g *** 4.2 ± 0.0 mg/g 
Placebo 4.9  ± 0.1 mg/g 4.7 ± 0.0 mg/g 
Fenofibrate 4.8 ± 0.1 mg/g 4.7 ± 0.1 mg/g 
Ramipril 4.1 ± 0.0 mg/g *** 4.6 ± 0.2 mg/g 
n= 16 (WT), 8 (KO); mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis 
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Table 4: Relative left ventricular weight of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham  3.5 ± 0.0 mg/g *** 3.4 ± 0.0 mg/g 
Placebo 4.1 ± 0.1 mg/g 3.9 ± 0.1 mg/g 
Fenofibrate 3.9 ± 0.1 mg/g 3.9 ± 0.1 mg/g 
Ramipril 3.2 ± 0.1 mg/g *** 3.7 ± 0.2 mg/g 
n= 16 (WT), 8 (KO); mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis 
 
Table 5: Relative right ventricular weight of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 0.83 ± 0.02 mg/g 0.85 ± 0.02 mg/g 
Placebo 0.83 ± 0.02 mg/g 0.86 ± 0.02 mg/g 
Fenofibrate 0.84 ± 0.02 mg/g 0.84 ± 0.02 mg/g 
Ramipril 0.81 ± 0.02 mg/g 0.83 ± 0.04 mg/g 
n= 16 (WT), 8 (KO); mean ± SEM 
 
Table 6: Relative lung weight of WT and KO mice after nine weeks 
 WT mice KO mice 
Sham 5.0 ± 0.1 mg/g 5.4 ± 0.1 mg/g 
Placebo 5.0 ± 0.1 mg/g 5.3 ± 0.1 mg/g 
Fenofibrate 4.9 ± 0.1 mg/g 5.5 ± 0.1 mg/g 
Ramipril 4.9 ± 0.1 mg/g 5.5 ± 0.1 mg/g 
n= 16 (WT), 8 (KO); mean ± SEM 
 
Table 7: Relative liver weight of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 42.2 ± 0.7 mg/g 45.9 ± 2.1 mg/g 
Placebo 42.3 ± 0.8 mg/g 45.8 ± 1.5 mg/g 
Fenofibrate 70.9 ± 0.9 mg/g *** 49.2 ± 1.6 mg/g 
Ramipril 45.8 ± 0.1 mg/g ** 45.2 ± 1.3 mg/g 
n= 16 (WT), 8 (KO); mean ± SEM; ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by 
Student-Newmann-Keuls post hoc analysis 
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Table 8: Relative right kidney weight of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 7.0 ± 0.1 mg/g 6.8 ± 0.2 mg/g 
Placebo 7.0 ± 0.1 mg/g 6.7 ± 0.1 mg/g 
Fenofibrate 7.6 ± 0.1 mg/g *** 6.7 ± 0.1 mg/g 
Ramipril 7.1 ± 0.1 mg/g 7.0 ± 0.2 mg/g 
n= 16 (WT), 8 (KO); mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis 
 
Table 9: Heart rate of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 443 ± 11 bpm 382 ± 15 bpm 
Placebo 437 ± 10 bpm 343 ± 13 bpm 
Fenofibrate 454 ± 9 bpm 339 ± 12 bpm 
Ramipril 453 ± 12 bpm 337 ± 16 bpm 
n= 16 (WT), 8 (KO); mean ± SEM 
 
Table 10: Left ventricular systolic pressure of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 117 ± 1 mmHg 113 ± 3 mmHg ** 
Placebo 111 ± 3 mmHg 92 ± 2 mmHg 
Fenofibrate 110 ± 2 mmHg 90 ± 3 mmHg 
Ramipril 91 ± 2 mmHg *** 76 ± 3 mmHg ** 
n= 16 (WT), 8 (KO); mean ± SEM; ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by 
Student-Newmann-Keuls post hoc analysis 
 
Table 11: Left ventricular end-diastolic pressure of WT and KO cMI mice after eight weeks of 
treatment 
 WT mice KO mice 
Sham 10.2 ± 1.0 mmHg * 6.0 ± 0.9 mmHg 
Placebo 13.5 ± 0.7 mmHg 10.8 ± 1.7 mmHg 
Fenofibrate 12.0 ± 0.7 mmHg 12.1 ± 2.6 mmHg 
Ramipril 10.2 ± 0.7 mmHg * 9.5 ± 0.7 mmHg 
n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis 
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Table 12: Contractility of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 7685 ± 146 mmHg/s *** 7613 ± 426 mmHg/s ** 
Placebo 6574 ± 152 mmHg/s 4630 ± 198 mmHg/s 
Fenofibrate 7273 ± 203 mmHg/s * 4679 ± 230 mmHg/s 
Ramipril 6792 ± 126 mmHg/s 4050 ± 424 mmHg/s 
n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05, ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, 
followed by Student-Newmann-Keuls post hoc analysis 
 
Table 13: Relaxation of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham -8986 ± 409 mmHg/s *** -7714 ± 480 mmHg/s ** 
Placebo -6482 ± 226 mmHg/s -4244 ± 240 mmHg/s 
Fenofibrate -7184 ± 237 mmHg/s -4028 ± 154 mmHg/s  
Ramipril -7436 ± 164 mmHg/s -3440 ± 314 mmHg/s 
n= 16 (WT), 8 (KO); mean ± SEM; ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by 
Student-Newmann-Keuls post hoc analysis 
 
Table 14: Relaxation constant tau of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 12.4 ± 0.6 ms *** 14.0 ± 1.0 ms ** 
Placebo 19.4 ± 1.1 ms 33.3 ± 3.4 ms 
Fenofibrate 16.6 ± 1.0 ms 32.7 ± 3.9 ms 
Ramipril 13.8 ± 1.0 ms *** 30.4 ± 2.7 ms 
n= 16 (WT), 8 (KO); mean ± SEM; ** p<0.01, *** p<0.001 vs respective Placebo ; ANOVA, followed by 
Student-Newmann-Keuls post hoc analysis 
 
Table 15: PPARα mRNA expression of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 1724 ± 1230 AU *** 1808 ± 261 AU 
Placebo 799 ± 399 AU 1336 ± 348 AU 
Fenofibrate 755 ± 335 AU 1485 ± 249 AU  
Ramipril 611 ± 282 AU 1340 ± 321 AU 
AU: arbitrary units; n= 16 (WT), 8 (KO); mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, 
followed by Student-Newmann-Keuls post hoc analysis 
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Table 16: PDK-4 mRNA expression of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 5041 ± 3345 AU  3426 ± 1433 AU  
Placebo 4083 ± 2325 AU 1785 ± 836 AU 
Fenofibrate 2930 ± 885 AU 2161 ± 513 AU 
Ramipril 2411 ± 850 AU 2805 ± 1702 AU  
AU: arbitrary units; n= 16 (WT), 8 (KO); mean ± SEM 
 
Table 17: ANP mRNA expression of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 103962 ± 63242 AU *** 45774 ± 11672 AU * 
Placebo 289958 ± 179822 AU 141053 ± 38669 AU 
Fenofibrate 205835 ± 108855 AU * 127032 ± 38479 AU 
Ramipril 152525 ± 63870 AU ** 181239 ± 64050 AU 
AU: arbitrary units; n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05, ** p<0.01, *** p<0.001 vs respective 
Placebo ; ANOVA, followed by Student-Newmann-Keuls post hoc analysis 
 
Table 18: MyHCβ mRNA expression of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 941 ± 651 AU ** 6453 ± 1314 AU 
Placebo 2525 ± 1919 AU 24503 ± 7753 AU 
Fenofibrate 1298 ± 833 AU ** 21906 ± 17562 AU 
Ramipril 756 ± 605 AU *** 20766 ± 9843 AU 
AU: arbitrary units; n= 16 (WT), 8 (KO); mean ± SEM; ** p<0.01, *** p<0.001 vs respective Placebo; 
ANOVA, followed by Student-Newmann-Keuls post hoc analysis 
 
Table 19: Collagen 1A1 mRNA expression of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 3959 ± 2501 AU 7143 ± 1443 AU * 
Placebo 4718 ± 2453 AU 17706 ± 4294 AU 
Fenofibrate 3784 ± 1418 AU 17476 ± 5113 AU 
Ramipril 3586 ± 1308 AU 17914 ± 6343 AU 
AU: arbitrary units; n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05 vs respective Placebo; ANOVA, 
followed by Student-Newmann-Keuls post hoc analysis 
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Table 20: TIMP1 mRNA expression of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 134 ± 74 AU ** 509 ± 182 AU * 
Placebo 428 ± 316 AU 2491 ± 497 AU 
Fenofibrate 350 ± 171 AU 2184 ± 757 AU 
Ramipril 263 ± 119 AU 4218 ± 1699 AU * 
AU: arbitrary units; n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05, ** p<0.01 vs respective Placebo; 
ANOVA, followed by Student-Newmann-Keuls post hoc analysis 
 
Table 21: OPN mRNA expression of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 1073 ± 2824 AU  15 ± 4 AU * 
Placebo 2908 ± 3999 AU 273 ± 42 AU 
Fenofibrate 1949 ± 1359 AU 351 ± 293 AU 
Ramipril 1261 ± 1309 AU 613 ± 233 AU * 
AU: arbitrary units; n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05 vs respective Placebo; ANOVA, 
followed by Student-Newmann-Keuls post hoc analysis 
 
Table 22: Plasma triglycerides of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 125 ± 41 mg/dL 113 ± 27 mg/dL 
Placebo 108 ± 29 mg/dL 140 ± 54 mg/dL 
Fenofibrate 99 ± 37 mg/dL 146 ± 71 mg/dL 
Ramipril 104 ± 28 mg/dL 123 ± 25 mg/dL 
n= 16 (WT), 8 (KO); mean ± SEM 
 
Table 23: Plasma total cholesterol of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 105 ± 10 mg/dL 128 ± 6 mg/dL 
Placebo 113 ± 15 mg/dL 120 ± 9 mg/dL 
Fenofibrate 160 ± 17 mg/dL *** 136 ± 14 mg/dL * 
Ramipril 122 ± 12 mg/dL 132 ± 9 mg/dL 
n= 16 (WT), 8 (KO); mean ± SEM; * p<0.05, *** p<0.001 vs respective Placebo; ANOVA, followed by 
Student-Newmann-Keuls post hoc analysis 
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Table 24: Plasma HDL of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 95 ± 7 mg/dL 126 ± 12 mg/dL 
Placebo 102 ± 16 mg/dL 119 ± 11 mg/dL 
Fenofibrate 151 ± 22 mg/dL *** 136 ± 15 mg/dL 
Ramipril 108 ± 12 mg/dL 132 ± 18 mg/dL 
n= 16 (WT), 8 (KO); mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis 
 
Table 25: Plasma LDL of WT and KO cMI mice after eight weeks of treatment 
 WT mice KO mice 
Sham 3 ± 2 mg/dL 7 ± 2 mg/dL 
Placebo 5 ± 3 mg/dL 6 ± 3 mg/dL 
Fenofibrate 16 ± 6 mg/dL *** 7 ± 2 mg/dL 
Ramipril 5 ± 2 mg/dL 8 ± 2 mg/dL 
n= 16 (WT), 8 (KO); mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis 
 
12.3.2 DOCA model 
 
Table 26: Body weight of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 30.2 ± 0.8 g ** 25.1 ± 1.0 g 
Placebo 26.8 ± 0.5 g 25.4 ± 0.5 g 
Fenofibrate 28.8 ± 0.6 g * 25.5 ± 0.6 g 
Ramipril 27.0 ± 0.6 g 26.4 ± 0.4 g 
n= 15; mean ± SEM; * p<0.05, ** p<0.01 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis 
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Table 27: Relative heart weight of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 4.4 ± 0.1 mg/g *** 4.3 ± 0.0 mg/g *** 
Placebo 5.1 ± 0.1 mg/g 5.6 ± 0.3 mg/g 
Fenofibrate 4.9 ± 0.1 mg/g * 5.2 ± 0.2 mg/g 
Ramipril 4.8 ± 0.1 mg/g * 4.7 ± 0.1 mg/g ** 
n= 15; mean ± SEM; * p<0.05, ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by 
Student-Newmann-Keuls post hoc analysis 
 
Table 28: Relative left ventricular weight of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 3.5 ± 0.1 mg/g *** 3.5 ± 0.0 mg/g *** 
Placebo 4.3 ± 0.1 mg/g 4.7 ± 0.2 mg/g 
Fenofibrate 4.0 ± 0.1 mg/g **  4.4 ± 0.1 mg/g 
Ramipril 4.0 ± 0.1 mg/g * 3.9 ± 0.1 mg/g ** 
n= 15; mean ± SEM; * p<0.05, ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by 
Student-Newmann-Keuls post hoc analysis 
 
Table 29: Relative right ventricular weight of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 0.87 ± 0.02 mg/g 0.86 ± 0.02 mg/g 
Placebo 0.84 ± 0.02 mg/g 0.92 ± 0.09 mg/g 
Fenofibrate 0.83 ± 0.03 mg/g 0.87 ± 0.03 mg/g 
Ramipril 0.81 ± 0.02 mg/g 0.76 ± 0.02 mg/g 
n= 15; mean ± SEM 
 
Table 30: Relative lung weight of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 5.1 ± 0.1 mg/g 5.3 ± 0.1 mg/g 
Placebo 5.4 ± 0.1 mg/g 5.8 ± 0.1 mg/g 
Fenofibrate 5.2 ± 0.1 mg/g 5.9 ± 0.3 mg/g 
Ramipril 5.3 ± 0.1 mg/g 5.5 ± 0.1 mg/g 
n= 15; mean ± SEM 
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Table 31: Relative liver weight of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 44.1 ± 1.3 mg/g *** 43.4 ± 1 mg/g *** 
Placebo 57.8 ± 1.4 mg/g 66.4 ± 1.8 mg/g 
Fenofibrate 98.9 ± 3.1 mg/g *** 69.8 ± 2.0 mg/g 
Ramipril 58.1 ± 1.6 mg/g 61.8 ± 1.3 mg/g 
n= 15; mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, followed by Student-Newmann-
Keuls post hoc analysis 
 
Table 32: Relative right kidney weight of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 6.9 ± 0.2 mg/g *** 7.2 ± 0.1 mg/g *** 
Placebo 12.5 ± 0.2 mg/g 14.9 ± 0.3 mg/g 
Fenofibrate 13.5 ± 0.3 mg/g ** 13.6 ± 0.4 mg/g * 
Ramipril 13.6 ± 0.3 mg/g * 14.3 ± 0.4 mg/g 
n= 15; mean ± SEM; * p<0.05, ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by 
Student-Newmann-Keuls post hoc analysis 
 
Table 33: Heart rate of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 442 ± 9 bpm 474 ± 10 bpm 
Placebo 425 ± 13 bpm 504 ± 13 bpm 
Fenofibrate 444 ± 8 bpm 498 ± 12 bpm 
Ramipril 440 ± 11 bpm 508 ± 19 bpm 
n= 15; mean ± SEM; * p<0.05 vs respective Placebo; ANOVA, followed by Student-Newmann-Keuls 
post hoc analysis 
 
Table 34: Left ventricular systolic pressure of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 120 ± 2 mmHg *** 115 ± 2 mmHg ** 
Placebo 143 ± 3 mmHg 133 ± 5 mmHg 
Fenofibrate 143 ± 3 mmHg 135 ± 4 mmHg 
Ramipril 132 ± 3 mmHg 132 ± 4 mmHg 
n= 15; mean ± SEM; ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis 
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Table 35: LVEDP of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 11.7 ± 1.0 mmHg 7.6 ± 0.7 mmHg 
Placebo 8.1 ± 1.3 mmHg 9.6 ± 1.0 mmHg 
Fenofibrate 10.8 ± 0.9 mmHg 9.7 ± 0.9 mmHg 
Ramipril 8.5 ± 1.6 mmHg 10.0 ± 0.7 mmHg 
n= 15; mean ± SEM 
 
Table 36: Contractility of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 7784 ± 219 mmHg/s 8054 ± 146 mmHg/s 
Placebo 8924 ± 366 mmHg/s  8948 ± 269 mmHg/s 
Fenofibrate 8536 ± 278 mmHg/s 8749 ± 346 mmHg/s 
Ramipril 8513 ± 278 mmHg/s 8737 ± 350 mmHg/s 
n= 15; mean ± SEM 
 
Table 37: Relaxation of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham -9251 ± 390 mmHg/s  -10066 ± 360 mmHg/s 
Placebo -9952 ± 777 mmHg/s -9237 ± 398 mmHg/s 
Fenofibrate -9628 ± 593 mmHg/s -9031 ± 578 mmHg/s 
Ramipril -10313 ± 673 mmHg/s -9289 ± 490 mmHg/s 
n= 15; mean ± SEM 
 
Table 38: Relaxation constant tau of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 12.7 ± 0.8 ms 11.5 ± 1.1 ms 
Placebo 14.8 ± 1.2 ms 15.6 ± 1.7 ms 
Fenofibrate 14.4 ± 1.0 ms 16.7 ± 2.0 ms 
Ramipril 12.4 ± 1.0 ms 16.8 ± 1.5 ms 
n= 15; mean ± SEM 
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Table 39: Baseline urine parameters of WT and KO mice 
 Volume 
(mL) 
Protein/Creatinine 
(g/mmol) 
Urea 
(mmol/L) 
Na+/K+ 
(mmol/L) 
Sham WT 1.4 ± 0.2 0.8 ± 0.1 796 ± 70 0.5 ± 0.1 
Placebo WT 1.3 ± 0.1 0.8 ± 0.0 823 ± 87 0.6 ± 0.1 
Feno WT 1.3 ± 0.2 0.7 ± 0.1 1006 ± 95 0.4 ± 0.1 
Ramipril WT 1.4 ± 0.2 0.8 ± 0.1 1049 ± 130 0.5 ± 0.0 
Sham KO 1.0 ± 0.2 1.0 ± 0.1 998 ± 134 0.5 ± 0.0 
Placebo KO 1.2 ± 0.1 1.4 ± 0.3 $ 836 ± 102 0.5 ± 0.0 
Feno KO 1.2 ± 0.2 1.2 ± 0.1 $$ 980 ± 156 0.5 ± 0.1 
Ramipril KO 1.0 ± 0.1 1.4 ± 0.2 $$ 935 ± 102 0.4 ± 0.0 
n= 15; mean ± SEM; $ p<0.05, $$ p<0.01 vs respective WT group; unpaired t-test 
 
Table 40:  Urine parameters of WT and KO mice after five weeks of treatment  
 Volume 
(mL) 
Protein/Creatinine 
(g/mmol) 
Urea 
(mmol/L) 
Na+/K+ 
(mmol/L) 
Sham WT 1.3 ± 0.2 1.5 ± 0.2 *** 877 ± 125 *** 0.5 ± 0.1 ** 
Placebo WT 3.7 ± 0.9 3.1 ± 0.3 335 ± 37 2.3 ± 0.3 
Feno WT 4.1 ± 0.5 2.6 ± 0.3 346 ± 19 2.4 ± 0.3 
Ramipril WT 4.8 ± 0.9 2.2 ± 0.2 * 290 ± 42 3.0 ± 0.6 
Sham KO 1.2 ± 0.2 * 1.0 ± 0.1 *** 823 ± 89 ***  0.8 ± 0.1 ** $ 
Placebo KO 6.4 ± 1.0 4.4 ± 0.6 $ 216 ± 47 4.6 ± 0.9 $ 
Feno KO 5.1 ± 1.0  3.5 ± 0.5 234 ± 21 $$$ 3.2 ± 0.5 $ 
Ramipril KO 9.0 ± 1.6 $ 3.0 ± 0.4 156 ± 31 $ 5.7 ± 0.8 $ 
n= 15; mean ± SEM; * p<0.05, *** p<0.001 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis; $ p<0.05, $$$ p<0.001 vs respective WT group; unpaired t-test 
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Table 41:  Differences between baseline and final urine parameters of WT and KO mice 
 ∆ Volume 
(mL) 
∆ 
Protein/Creatinine 
(g/mmol) 
∆ Urea 
(mmol/L) 
∆ Na+/K+ 
(mmol/L) 
Sham WT 0.1 ± 0.3 * 0.7 ± 0.3 *** 88 ± 109 * 0.0 ± 0.1 * 
Placebo WT 2.4 ± 0.9 2.3 ± 0.3 -487 ± 104 1.7 ± 0.4 
Feno WT 2.9 ± 0.6 1.9 ± 0.3 -659 ± 101 1.9 ± 0.3 
Ramipril WT 3.6 ± 0.8 1.4 ± 0.2 * -760 ± 146 2.5 ± 0.6 
Sham KO 0.2 ± 0.2 * -0.0 ± 0.1 ** $ -175 ± 100 0.3 ± 0.1 ** 
Placebo KO 5.3 ± 1.2 3.1 ± 0.8 -616 ± 134 4.1 ± 0.9 $ 
Feno KO 4.1 ± 1.1 2.3 ± 0.4 -755 ± 165 2.7 ± 0.5 
Ramipril KO 7.5 ± 1.7 * $ 1.5 ± 0.3 -755 ± 127 4.9 ± 0.8 $ 
n= 15; mean ± SEM; * p<0.05, ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by 
Student-Newmann-Keuls post hoc analysis; $ p<0.05, respective WT group; unpaired t-test 
 
Table 42: PPARα mRNA expression of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 1426 ± 51 AU  868 ± 260 AU ** 
Placebo 1548 ± 273 AU 428 ± 167 AU  
Fenofibrate 1072 ± 188 AU ** 527 ± 267 AU  
Ramipril 1356 ± 245 AU 462 ± 92 AU 
AU: arbitrary units; n=15; mean ± SEM; * p<0.05, ** p<0.01 vs respective Placebo; ANOVA, followed 
by Student-Newmann-Keuls post hoc analysis 
 
Table 43: PDK-4 mRNA expression of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 32130 ± 13752 AU  19954 ± 4178 AU  
Placebo 20098 ± 7779 AU 11424 ± 5111 AU 
Fenofibrate 14485 ± 7611 AU 16510 ± 9302 AU 
Ramipril 23170 ± 5751 AU 19073 ± 4295 AU  
AU: arbitrary units; n= 16 (WT), 8 (KO); mean ± SEM 
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Table 44: ANP mRNA expression of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 618157 ± 142706 AU ** 621687 ± 208450 AU * 
Placebo 1868295 ± 729347 AU 2650689 ± 1698254 AU 
Fenofibrate 1377982 ± 331739 AU 2429437 ± 807745 AU 
Ramipril 1313209 ± 368028  AU 1576410 ± 474767 AU 
AU: arbitrary units ; n= 15; mean ± SEM; * p<0.05, ** p<0.01 vs respective Placebo; ANOVA, followed 
by Student-Newmann-Keuls post hoc analysis 
 
Table 45: MyHCβ mRNA expression of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 1531 ± 630 AU *  4550 ± 2101 AU $ 
Placebo 5074 ± 2085 AU 8368 ± 6582 AU 
Fenofibrate 3560 ± 1447  AU 10009 ± 7148 AU 
Ramipril 4798 ± 1943  AU 9304 ± 4206 AU 
AU: arbitrary units ; n= 15; mean ± SEM; * p<0.05 vs respective Placebo; ANOVA, followed by 
Student-Newmann-Keuls post hoc analysis; $ p<0.05 vs Sham WT; unpaired t-test 
 
Table 46: Collagen 1A1 mRNA expression of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 28942 ± 8562 AU 21873 ± 8853 AU 
Placebo 33564 ± 13290 AU 46467 ± 34332 AU 
Fenofibrate 34869 ± 5540 AU 50824 ± 31685 AU 
Ramipril 28339 ± 3309 AU 32936 ± 10483 AU 
AU: arbitrary units; n= 15; mean ± SEM 
 
Table 47: TIMP1 mRNA expression of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 753 ± 247 AU * 767 ± 257 AU 
Placebo 2087 ± 1080 AU  3380 ± 2331 AU 
Fenofibrate 1718 ± 379 AU 2915 ± 1951 AU 
Ramipril 1395 ± 635 AU 1226 ± 161 AU 
AU: arbitrary units ; n= 15; mean ± SEM; * p<0.05 vs respective Placebo; ANOVA, followed by 
Student-Newmann-Keuls post hoc analysis 
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Table 48: OPN mRNA expression of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 139 ± 84 AU  98 ± 27 AU  
Placebo 456 ± 400 AU 828 ± 899 AU 
Fenofibrate 276 ± 111 AU 877 ± 552 AU 
Ramipril 223 ± 75 AU 221 ± 47 AU  
AU: arbitrary units; n= 16 (WT), 8 (KO); mean ± SEM 
 
Table 49: Plasma triglycerides of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 86 ± 25 mg/dL 99 ± 34 mg/dL * 
Placebo 120 ± 74 mg/dL 148 ± 65 mg/dL 
Fenofibrate 94 ± 38 mg/dL 145 ± 39 mg/dL 
Ramipril 119 ± 44 mg/dL 163 ± 49 mg/dL 
n= 15; mean ± SEM; * p<0.05 vs respective Placebo; ANOVA, followed by Student-Newmann-Keuls 
post hoc analysis 
 
Table 50: Plasma total cholesterol of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 99 ± 10 mg/dL ** 122 ± 8 mg/dL *** 
Placebo 173 ± 66 mg/dL 255 ± 84 mg/dL 
Fenofibrate 162 ± 38 mg/dL 208 ± 54 mg/dL 
Ramipril 169 ± 40 mg/dL 251 ± 96 mg/dL 
n= 15; mean ± SEM; ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis 
 
Table 51: Plasma HDL cholesterol of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 126 ± 14 mg/dL *** 146 ± 9 mg/dL *** 
Placebo 224 ± 55 mg/dL 286 ± 98 mg/dL 
Fenofibrate 218 ± 44 mg/dL 261 ± 70 mg/dL 
Ramipril 206 ± 50 mg/dL 279 ± 98 mg/dL 
n= 15; mean ± SEM; *** p<0.001 vs respective Placebo; ANOVA, followed by Student-Newmann-
Keuls post hoc analysis 
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Table 52: Plasma LDL cholesterol of WT and KO mice after six weeks of treatment 
 WT mice KO mice 
Sham 3 ± 2 mg/dL *** 7 ± 2 mg/dL ** 
Placebo 27 ± 14 mg/dL 48 ± 20 mg/dL 
Fenofibrate 27 ± 12 mg/dL 38 ± 12 mg/dL 
Ramipril 20 ± 12 mg/dL 43 ± 30 mg/dL 
n= 15; mean ± SEM; ** p<0.01, *** p<0.001 vs respective Placebo; ANOVA, followed by Student-
Newmann-Keuls post hoc analysis 
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